06.RBJIEH11E 3A B1,3Jl0llCEHA nOP1,lfl(A ( oepc•• 7)

Ilpff'l'YPKB K"hM 0cl>H�8JleH eeCTHHK Ha EepooeiicKHJI C'l>J03

liRcpopMauHJl a 0HJ1ai!R q>opMyAApH: http://sjmap.ted.europa.eu

06HBJIEHHE3ABn3JIOmEHAUOP'b'IKA

PeayJITBTH OT opon;e.ZJYP8T8 38 B'b3Jlar8He H8 o6oxeCTBeHa D0p'1>'1K8

,llHpeKTHBa 2014/24/EC / 300 QTipoe1<T Ha o6stBJJeHHe l8]06stBJJeRHe aa oy6nHJCYBaHe

PA3.l(EJI I: B1>3JIAI'AIU OPrAH I.1) HaHMeHOBaHHe H 8A}>eCH 1 (MOJI.JI, noconere BCH'IKH B'b3Jlar�H opraan, KOHTO orroaapar aa nponenypara) Oq>HUHaJJHO HaHMeHOBaHHe: HauHOHaJJeH peracrpauaoaea ROMep: 2 YHMBepCMTeTCKa MHoronpo�MJlHa 60JlH"1Ua 3a 102274111 aKTMBHO neYeHMe - Byprac A)l Ilo11.1eHCKH azrpec: 6yn. CTe�aH CTaM5onos Nt 73 I'paa: I K0,1:1 NUTS: fio11.1eHCKH K0,11.: I .lhp)Kaaa: Byprac BG341 8000 BG .JlHue aa KOHTaKT: Tenerpoa: Yipe Ha DeTKOBa +359 879358008 EneKTpOHHa 0011.1a: <J>axc: mbalburgas8000@gmail.com +359 56810592 11HTepHeT a,o.pec/H Ocaoaea aapec (URL): http://www.mbalburgas.com/ Anpec Ha npotpana Ha KYOYBa<1a (URL): http://www.mbalburgas.com/bg/news/index/58/ I.2) ObeMeCTHO B'b3JlaraHe QfiOp-b'IKaTa ofixaama C'bBMeCTHO B'b3JlaraHe

B CJl)"laM Ra C'bBMeCTHo B'b3JlaraHe, ofixeamamo pa3JJH'IHH ,11.1,p)Kal!H - opHJJO)KHMOTO HaUHOHaJJHO 38KOHO,naTeJJCTBO B cq>epaTa Ra ofinrecraemrre OOp-b'IIOI:

nTIOP1>'1KaTa Ce B1>3JJara OT UeHTPaJJ6H 0Pf3H sa DOKYTIKH

I.4) B� na B'b3Jlar� opran 0MHHHCTepCTBO HJIH BCJlK8K1>B zrpyr HaUHORaJJeH 181 Ily6J11cNHOOpaBHa opraHH3aUWI

WlH <t>e.a.epaneH opraa, BKJIIO'IWfeJJHO TeXRH

perHOHaJJHH HJIH MeCTJHI OOApaa.11.eneHH.Sl OHaunoHanHa H.Jm <1>e.11.epa1rna areHUWI/CJJJ)K6a 0EapoaeRcKa HHCTHTYUHJl/areHUHR HJJH

Me)l(,ll.yHapo,11.HaoprattnaauHjj 0PernonaneH KJIH MeCTeH opraa QJ:{pyrrnn: nPerHOHaJJHa HJIH MeCTHa areRUHJI/CJJY)K6a

I.5) Oeaoena AeHHOCT 006U{H 0611.1eCTBeRH ycnyru 0HacraHS!BaHe/)KHJ1Hll.lHO CTpOHTeJJCTBO 11 MeCTa

aa OT.II.WC H J<YllTYPa QOT6paua 0Cou11anHa aaspana 00611.1ecraee pea H fieaonacaocr OOT.11.HX, xyrrrypa 11 aepoaanoaeaaaae OOKonHa cpezta 006pa30B3HHe 011KOHOMJftleCKH H cp1rnaHCOBH .11.eKHOCTH QJ:{pyra .11.eiiHocr: tSa3.11.oaaeona3eaHe

PA3,l(EJI II: IlPE,l(MET II.1) 06XBBT H8 o6oxeCTBenaTa DOP'l>'lK8

11.1.1) H8.HMeHOB8.HHe: ,,llOCTaBKa Ha neKapCTBeHM npo�yKTM /c�rnaCHO cneuMtMKaU"1A/ 3a HY��"1Te Ha ,,MHoronpO�MJlHa 60JlHMU,a 3a aKTJ.1BHO JleYeHMe - Byprac" A.[\" Pediepeareu 1:10Mep: 2

Il.1.2) Oenoaen CPV KOA: .Uon-1>11RHTeneH CPV xon: 1 2

YHn e6d020c:a·b l b9-4.0CS.b987 -d6b4S8968clS

33690000

Otl)TlllUI 06JIB.l!EAHE 3A B1>3JIOlKEHA OOP'b'OCA (ocpao 7)

Il.1.3) BUA ea nop-smea Cr OBTe.JlCTBO )lOCTaBKH H

Il.1.4) KpaTKO onacaane: 05eKT Ha nop�YKaTa ca nep!IIO..QIIIYHO noaTapRW!II ce ..QOCTaBK!II Ha neKapCTBeH!II npo..QyKT!II aa HY)KW:1Te Ha ,,MBAJl - Syprac" A,IJ,. JleKapCTBeH!IITe npO..QYKT!II ca on111caH111 no.npo5HO B cneu111�111KaUIIIRTa, !<ORTO ce RBRBa Hepa3..QenHa YaCT OT HaCTORWaTa ..QOKyMaTaUIIIR, no reHep!IIYH!II Ha!IIMeHOBaH!IIR (INN) 111n111 .npyr111 HenaTeHTH!II Ha111MeHOBaHIIIR, neKapcTBeH!II �OpM!II III Cb..Qbp)KaH111e Ha aKT!IIBHOTO neKapcTaeHo aewecTao, 06ocoOeH111 a no3111u111111, BKn�Yaaw111 pa3n111YeH 5po� HOMeHKRaTypH!II e..QIIIH!IIUIII (eneMeHT!II B n03!11U!IIRTa). JleKapCTBaTa ca rpyn111paH111 B 143 5p. o6oco0eH!II n03111UIIIIII, BKR�Yaaw111 CbOTBeTHIIITe HOMeHKTypH!II e..Q!IIHIIIUIII, CbrnaCHO TeXHIIIYeCKa cneu111�111Kau111R. ll.1.6) lbul>opM� OTHocno o6oco6eRHTe noaHWDt Hacrosurara no qKa e aaaenena Ha ofiocofiena n03Bl.lHH .Ua 181 He D ll.1.7) 06�a CTOHHOCT Ha o6�eCTBeHaTa nop-ssnca (6ea Aa ce BKJUO'IBa MC) OroiiHoCT: (Mo1111, nocoxeme 06U4ama cmoi1Hocm Ha 06U4ecmaeHama nOJrl>4Ka. 3a u1t!fjopMa4Wl omHOCHO UHOU6UGyQJIHU nOJ)'l,4KU, MOIIR, U3n0/136ai1me pa30e/l V) RJIH HaH-HHCKa orpepra: / HaH-BHCOKa odiepra: KOBTO ca B3eTH ape,UBH.U Banyra: BGN (sa pa.,.1,coeu cnopa3yMeHWl - o6U4a MOKCUMWIHa cmoi1Hocm 3a l{Rllama npOOl>IDKUme/lHOCm) (3a OUHOMU4KU cucmeMu 3a no,cynKU - cmoiiuocm Ha nopvocama/ume, xoamo/xoumo Hee/ca a1U1104e1ta/u a npeinnunu o6R6/leHWl 3a 8b311aeaHe Ha nOJ)'l,4KU) (sa nopl>'OCU, 6a3upaHu Ka pOMKoau cnopasuueuus; cxo moaa ce U3UCK6a - cmoiiuocm Ha no 4Kama ume, KORmo xourno He e ca BJU1104eHa u a n eouwHu o6R611eHWl 3a B"f,3/laeaHe Ha no "f>4KU)

PA3,l];EJI II: Orracamre / 06oco6eua noaHU.HJI 11.2) 0UHcaHHe 1

II.2.1) Hasuaenoaanaes 2

II - pa rpyna nep111�epH111 M!IIOpenaKCaHT!II (HepBHO-MyCKYRH!II Ono1<:ep111) Ofiocotieua a03HJ.lWI NQ: 8 2

n.2.2) .l(on"bJIHHTeJJHH CPV xoaoae 2 OcHOBeH CPV xon: 1 33660000 .l(oa-bJJHHTe.neH CPV KO.U: 1 2

n.2.3) MBCTO Ha H31n>JlHeHHe 0CH08HO MnCTO Ha H30"bJ!HeHHe: OOflHIIIYHa an Te Ka KO.U NlITS: 1 BG341 II.2.4) 0UHcaHHe Ha o6�eCTBeHaTa nop'b'lxa: (eerecrao H KOJ1eqecrno Ha CTpOHTeJIHH pa60TH, .UOCTaBKH WJH ycnyra HJIH YKa3BaHe ea nOTpe6HOCTH a H3HCKBaewi) 8.3Rocuronium bromide lOmg/ml Smlsol.inj.Sugammadex 100 mg/ml 2 ml sol.inj.150 11.2.5) KpHTepHH sa e'b3Jlaraee 1 2 D KpeTepeA aa xaxecrso - 11Me: / Texcecr: 1 2 2° 181 Kparepaa, CJIT:,p3aH c pasxona - 11Me: / Te)KeCT: 1 2°

1 C111rypHOCT Ha ..QOCTaBKaTa 20 2 UeHa 80 n Ilexa - Tesceer: 21

11.2.11) llHfl>opM�HJI OTHOCHO OUD;HHTe Onuaa .l(a D He181 Onacanae Ha onuaare:

11.2.13) llHfl>OpM� OTHOCHO cpeaeraa OT EsponeHCKHJI C'bl03 .Ua D He181 Ofiuiecrsenara nopsxsa e m,e Bp,,3Ka c npoexr 11/WJH nporpaaa, q>HHa11c11paH/a csc

cpeacrsa OT Eepoueiicxna c,,103 11.AeHTHq>HKal.lHJI Ha npoexra:

YHO; o6d020ca-b I b9-410d-b987-d6b4S8968c2S 2

06JIBJIEH}{E 3A Bl,3JJQlKEHA OOP1,4KA (•cpCH• 7)

I II-2.14) )100...,.mn-enna Hn,j)opM...,..,

P A3,UFJI II: Orracaane / 06oco6eea D03HIQUI

II.2) OuucaHHe 1

II.2.1) HaHMeHOBaHHe: 2 Somatostatin 06oco6eua 003111.(lUI NQ: 68 2

II.2.2) .D:on'hJIHHTeJIHH CPV xoaoae 2 OcHoBeH CPV KOA: 1 33642000 .Uoa'bJlHHTeJieH CPV KOA: 1 2 -- II.2.3) Macro ea Han'hJIHeHHe 0CHOBHO MJICTO Ha H3D'bJIHeHHe: OOJ1Hv!YHa an Te Ka KOA NUfS:1 BG341 II.2.4) Orracansre 11a o6�eCTBeHaTa nop'l>qJ<a: (ecrecrso ff KOJIHtteCTBO Ha CTpOHTeJIHfl pa60TH, AOCTaBKH HJllf ycnyra HJUI YKa3BaHe Ha DOTpe6HOCT11 11 H3HCKBaHW1) lSomatostatin 3mg + solv.lmlpowd. inf.+ solv.300 II.2.5) KpHTepHH aa B'L3.llaraHe 1 2 O KpnTepnn aa xaseerao - l1Me: / Tescecr: 1 2 2° � KpHTepun, cm.paan c paaxozm - l1Me: / Tescecr: 1 2° 1 Cv1rypHOCT Ha .llOCTaBKaTa 20 2 UeHa 80 n Ileaa - Tescecr: 21

11.2.11) HH«t>opMaJ.(HJI OTBOCHO OilW{HTe 0DJ.{HH .ll:aO He� Onacaaae Ha 011QHHTe:

II.2.13) IIH«l>opMaJ.(HJI OTHocuo cpeneraa OT EBponeifclOUI C'l>J03 Otiuiecraeaara nopsxxa e BnB BJ)'b3Ka c npoeier n/HJIH nporpaxa, cjnntaHc11pau/a csc .ll:aO He� cpeaeraa OT Eaponeacxaa c,,103 l1AeHn1(t>BKaQWI Ha npoesra:

II.2.14) .D:on'hJIHHTeJIBa HH«l>opMaJ.(HJI:

P A3,UFJI II: Onncaeue / 06oco6eea D03HIQUI

II 2) OnHCaHHe 1 . 11.2.1) HBHMeBOBa.HHe: 2 J..llllTOCTaTv!U.1-1 - Ui-11<:Jioq>ocqiaMJ.1..a 06oco6eHa D03HqHR NQ: 100 2

II.2.2) .l]:Oil'hJIHHTeJJHH CPV xonoae 2 0CHOBeH CPV KO.I).: 1 33621100 .Uon'bJIHHTeJieH CPV KOA: 1 2

11.2.3) Macro Ha H3U'hJ1HeHHe OcHOBHO MJICTO ea H3D'bJ1HeHHe: OOJIHv!YHa anTeKa KOA NlITS:1 BG341 II.2.4) Omrcanae ua o6�eCTBeHaTa nop'l>�a: (ecrecrso H KOJJH'l.eCTBO Ha CTPOHTeJIHlf patioru, AOCTaBKH HJIH YCJIYfH HJIH yxaaaaae Ha DOTpe6HOCTH If lf3HCKBaHHJ1) 1001Cyclophosphamide 200 mgpowder for solution for injection

YHfl: e6d020ca-blb9-4a0d-b987-d6b458968c25

06.RBJIEHHE 3A 81,3RQ�"EHA OOPb'IKA (•t;>Ck• 7)

1002Cyclophosphamide 500 mgpowder for solution for injection II.2.5) KpHTepHH aa B'h3JlaraHe 1 2

D Kparepaa aa xasecrso - 11Me: / Te)KeCT: 1 2 2° 181 Kparepati, CB'bp3aH c paaxozra - 11Me: / Te)KeCT: 1 2° 1 CJ.1I'YPHOCT Ha .nocTaBK:aTa 20 2 J..teHa 80 n Ileaa - Te)KeCT: 2 l

II.2.11) HH(t,opM�HJI OTHOCHO omrmere Onuax .[{a D He181 Onacaaae Ha onuaare:

11.2.13) HH(t,OpMau;HJI OTHOCHO cpeACTB8 OT EBponeHCkHJI C'J.103 06meCTBeHaTa nopsxxa e B'bB apsaxa c npoexr e/wrn rrporpasra, q>11HaacHpaH/a esc .[{a D Hel81 cpeacraa OT EBpoaeiiCKHJI C'bI03 HJleHru¢11Ka1.1,1U1 Ha npoexra:

11.2.14) .[{OII'hJIHHTeJIHa HH(t,OpMa�:

PA3,ZJ;EJI II: Onncarrae / 06oco6eHa noamraa II.2) 0DHca.HHe 1

II.2.1) H8HMeHOB8HHe: 2

KXT-5ym1H 06oco6eHa noaarras NQ: 129 2

II.2.2) .[{OD'l,JJHHTCJJHH CPV KOAOBe 2

Ocaosea CPV KOJl: 1 33651500 )lon'hllRHTeneH CPV KOJl: 1 2

II.2.3) M.aCTo ua H3n'h.11HeHHe 0CHOBHO MJICTO Ha 113TI'hlJHeHHe: 50J1HMYHa anTe1<:a KOJl NUTS:1 BG341 II.2.4) Orracamre Ha ofimecraerrara nop-saxa: (ecrecrso H KOn111.1eCTBO Ha CTPOHTeJIHH pa60TH, JlOCTaBKH HJIH ycnyra HRH JKa3BaHe Ha 00Tpe6HOCTII 0 H3HCKBaHH.11) lHuman Immunoglobulin 100 -170 mg/ml (60 IO/ml) 3ml, /CHF-bulin/ sol.inj. II.2.5) KpHTepHH aa B'b3JlaraHe 1 2

D Kp11TepHH aa Ka1.1eCTBO - HMe: / Te)KeCT: 1 2 2° 181 Kparepaii, crrspaan c pasxona - HMe: / Te)KeCT: 1 2°

1 Ci-irypHOCT Ha .IlOCTaBK:aTa 20 2 UeHa 80 n Ileaa - Te)KeCT: 21

II.2.11) HH(t,opMa�H.R OTHOcHo omrmere Onu,HH .UaO He� Onacaaae aa onuaare:

II.2.13) HH(t,opMau;HJI OTHOCHO cpeJJ;CTBa OT EBponeHCKH.R C'bl03 .UaD He� Otimecraeaara uopsnxa e B'bB apsaxa c npoexr 11/11nn nporpasra, ¢HHaac11paH/a C'bC

cpencrsa or Esponeacxaa C'bl03 11JleHTH¢11.KaQHJ1 Ha npoesra:

ll.2.14) .[{Oll'l,JJHHTeJIH8 HH(t,OpM�H.R:

YHII. c6<1020ca·b I b9-4n0d-b987 -d6b458968c25

O&pntJJI' 06SIBJlllHl1E 3A Bl,lJIQlKEHA OOP1,4KA (1cpc1tM 7)

PA3�EJI II: Ouacaane / 06oco6eea noauu:KR 11.2) OrmcaHHe 1

11.2.1) HBHMeHOBB.HHe: 2 I - ea rpyna MeCTHll! aHeCTeTll!Ull! 06oco6eua D03HUH.» NQ: 5 2

ll.2.2) .l{Oll'l,JJHHTeJJHB CPV KOAOBe 2 Ocaosea CPV Ko,n: 1 33660000 .Uoa'b.ltHHTe.neu CPV KOA: 1 2

ll.2.3) M.acro ua H3n'h.llHeHHe 0CH08HO MJICTO Ha H3ITbJ1ReHHe: 50JJHW-. Ha anTeK:a KOA NUTS:1 BG'.l.dl U.2.4) 0IJHcaHHe ua ofirnecrneaa'ra nop'l>'IKa: (eCTeCTBO a KOJJH'leCTBO Ha crpOHTeJJHH pa60TH, .llOCTaBKH WIH ycnyra HJIH YK33BaRe Ha OOTpe6soCTH H B3HCKBaRRJ1) lLevobupivacaine 5 mg/ml lOmlinj.700 2Ropivacaine HCl 5 mg /ml 10 mlsolution for injectionlOO 3Ropivacaine HCl 7,5 mg /ml 10 mlsolution for injectionlOO ll.2.5) KpBTepHH aa B'b3JlaraHe 1 2 D Kp11Teptm aa Ka<1eCTBo - l1Me: / Tesceer: 1 2 2° � KpHTepHH, caspaae c paaxona - HMe: / Tescecr: 1 2° 1 Cll!rypHOCT Ha ,l:IOCTaBK:aTa 20 2 I.le Ha 80 n Ileua - Teacecr: 21

U.2.11) Huct,opMa� OTHOCHO on�HHTe Oau1111 .naD He� Onacauae Ha OOUHHTe:

Il.2.13) HHct,opM� OTHOCHO cpeneraa OT EuponeHCKH.A C'bJ03 06uteCTBeRaTa OOp'h'IKa e B'hB apsasa c npoexr H/HJJH nporpaaa, q>HH3HCHpaH/a C'bC .naD He� cpeacraa OT Eaponeacxaa C'bl03 l1,D.eHTHq>RK3UHJI Ha npoexra:

Il.2.14) .l{Oil'l,JlHHTeJIH8 HHcl,OpM�:

P A3�EJI II: Onucauue / 06oco6eea noaarraa II 2) Orracaane 1

II.2.1) Haassenoaasraer 2 II - pa rpyna JlTI' noam,u1aa11.1111 K:p'bBTa, Kp'bBOHOCHt1Te C'b..QOBe 11 Mll!1<:pou111p1<:yJ1au11RTa 3a nepopaJJHO np11JJO)l(eH11e 06oco6eea no3HUHJI NQ: 53 2

II.2.2) .l{OII'l,JJHHTeJIHH CPV KOAOBe 2 Ocucaeu CPV KOA: 1 33621000 .Uon'hllHHTeneH CPV KOA: 1 2

Il.2.3) M.acro ua H311'b.11Heuae OcHOBHO MJICTO Ha H3D'hJIHeHHe: OOJ1Hl1YHa anTei<:a son NUTS: l BG'.l.dl U.2.4) OnHCBHHe na ofimecraena'ra nOp'l>'IKa: (ecrecrso H KOJJH'leC'reo Ha CTpOHTMHH pa60TH, .llOC.'TaBKH HJlH ycnyrH HJIH YK33BaHe Ha 00Tpe6HOCTH H H3HCKBa1nu1) 531Pentoxifyllin lOOmgtabl. film 532Vinpocetine lOmgtabl

Ytu I t6d020ca·b I b9-4a0d.-b987-d6b4S8968c2S

06.ffilJIEHHE 3A Bl,JJlOlKEHA nOP'b'iKA (scpCH• 7)

533Vinpocetine Srngtabl ll.2.5) KpHTepHH aa B'b3JlaraHe 1 2

O Kparepmi aa Ka4eCTeo - MMe: / Te>KeCT: 1 2 2° 181 Kparepaa, CB'bp3aH c pa3XOAH - MMe: / Te>KeCT: 1 2° 1 Clt!I'YPHOCT Ha .[(OCTaBKaTa 20 2 UeHa 80 n Ileua - Te>KeCT: 21

Il.2,11) HHtl>OpM� OTHOCHO omrmrre OnuHH J];a O He181 Onacanae ea ODUHHTe:

Il.2.13) HH4>opMaJ.OIJI OTHocHo cpenerna OT EBponei:icKKR C"bJOa Ofimecrseaara noptonca e B1>B apsaxa c rrpoexr H/wm nporpassa, q>HHaHcHpatt/a C'I,C J];a O He181 cpeneraa OT Esponeacsaa C'bl03 11..o.eHTHq>HKal..(IDI aa npoexra:

11.2.14) ,ll;OD'hJIHHTeJJHa HHtl>opMaJ.(HJI:

PA3,Z:J;.EJI II: Omtearrae / 06oco6eea noamraa ll.2) Omscanne 1

11.2.1) HaHMeHOB8HHe: 2

Octreotide Otiocofieaa D03HUHH NQ: 66 2

II.2.2) J];oil'hJIHHTeJJHH CPV Koµ;oee 2

Ocaoaea CPV KO,n: 1 33621000 .[(oD'bJIHHTe.nee CPV Ko,n: 1 2

11.2.3) MJICTO Ha H3Il'bJIHeHHe 0CHOBHO MJICTO Ha H3Il'bJ1HeHHe: 60J1Hl14Ha an Te Ka KOA NUTS:1 BGc-141 ll.2.4) Ormcamse Ha o6�eCTBeHaTa nop'h"IKa: (ecreerao H KOJIK�eCTBo Ha CTpORTeJlHH pa60TH, ,0.0CTaBKH rum: ycnyra HJUI yxaasane Ha DOTPe6HOCTH H H3KCKBaHHJI) lOctreotide O.lrng lrnlsol.inj .1700 II.2.5) KpHTepHH aa B'h3JlaraHe 1 2

O KpHTepHii sa Kat1eCTBo - MMe: / Teacecr: 1 2 2° 181 KpHTep11ii, CB'bp3aH c pasxozra - MMe: / Te>KeCT: 1 2° 1 CMI'ypHOCT Ha .[(OCTaBKaTa 20 2 lle aa 80 n Ilena -Te>KeCT: 21

II.2.11) HH4>opMau;HJ1 OTHOCHO onmoere 0DUHH AaD He181 Onacauae Ha ODUliHTe:

II.2.13) HHtl>OPMaJ.OIJI ornoeno cpencrna OT Eeponei:iCKKR C'hJOa Ofimecraeaara DOp-bt1Ka e e1,e apssxa c rrpoexr H/HJJH nporpassa, q>HHaHcHpaa/a csc AaO He181 cpencrsa OT Eaponeticxaa e1>10a li.ueHTHq>HKaUHJI Ha npoexra:

ll.2.14) Aon'l>JIHHTeJJHa HH4>0pMaJ.01J1:

YHfl: e6d020cs-blb9-4a0d-b987-d6b458968c25 6

llapn1a.

PA3.UFJI II: Onncaane / 06oco6eHa noaarma II.2) 0nHca.HHe 1

06RBIIEHHE 3A 8'blJJOlKEHA nOP'b'lKA (oepc•• 7)

II.2.1) HaHMeHoeaHHe: 2 I - ea rpyna rm. .Qe11tCTBa11t111 e1,pxy use Ofiocofieaa no3HUH11 N!!: 15 2

II.2.2) ,llOll'hJlHHTeJUIH CPV xoaoae 2 OcHoBeH CPV KOA: 1 33690000 )lon'bJlHHTeneH CPV KOA: 1 2

ll.2.3) Macro Ha H3D'b.llHeHHe OCHOBHO MllCTO aa H3D'bJJHem1e: an Te Ka Ha YMSAJ1 Syprac A,[{ KOA NUfS:1 BG�41 II.2.4) OnHCBHHe na 0611:(eC"rBeuaTa DOJYb'lX8: (eCTeCTBO H KOJIH'{eCTBo Ha crpoHTeJJHH pa60TH, AOCTaBKH HJIH ycnyra RJlH yxaaaaae Ha DOTpe6HOCTH Ii H311CKB3H1-IJI) 15.SSodium valproate/ Valproic acid 300mgtabl ll.2.5) KpHTepHH aa e'b3JlaraHe 1 2 D KpHTepHii sa xaxecrao - liMe: / Texcecr: 1 2 2° D KpHTepHH, CB'bp3aH c pa3XOAH - liMe: / Tescecr: 1 2° l5ll Ileaa -Texcecr: 21

II.2.11) Huct>opMaIOUI OTHocHo o�e Onuaa .llaD He� Onncaaae Ha onuaare:

11.2.13) UHcl>OPMaJ:OIJl OTHocuo cpeneraa OT EeponeHcKHR C'bJ03 06�eCTBeHaTa nopsxxa e B'bB spsaxa c npoexr H/HJIH nporpasia, q>HH3HCHpaR/a C'bC )la D He� cpencrsa OT Eaponeacxua C'b103 0AeHTHcj)R1<auHJ1 Ha npoexra:

ll.2.14) )lOD'hJIHHTe.JIH8 HHcfi0pM8�HR:

PA3.UFJI II: Onucanne / 06oco6eHa no3Hl(HJI 11.2) Onncamse 1

11.2.1) HBHMeHOBBHHe: 2 II - pa :rpyna nn. .ne111CTBa11t111 s1,pxy UHC 06oco6etta no3HUHJI N!!: 16 2

n.2.2) )lOII'b.llHJffeJIHH CPV KOJJ,OBe 2 Ocaoaeu CPV KOA: 1 33690000 ,Uoll'bJlHHTeneH CPV KOA: 1 2

Il.2.3) MBCTO Ha H31l'b.llHCHHC 0CHOBHO M11CTO Ha H30'bJIReHHe: anTeK:a Ha YMSAJ1 Byprac A,!l KOA NUTS: 1 BG341 Il.2.4) OnHCBHHe ua 0611:(ecreeHaTa nop'bqKa: (eerecrao H KOJIH\feCTBO Ha crpOHTeJJHl1 pa60Tl1, AOCT38KH HJll1 ycnyrn HJll1 YK33BaHe Ha DOTpe6HOCTH a 113RCKBaHfUI) 16.3Piracetam lg Smlinj. ll.2.5) KpHTepHB 38 e'b3JlarBHe 1 2 D KpHTepBH sa xaxecrao - HMe: / Texcecr: 1 2 2° D Kp11TepHH, cm-paaa c pa3XOAH - liMe: / Tescecr: 1 2° 121 Ileaa -Texcecr: 21

II.2.11) llucl>opM�HJI OTHOCHO ODJ.ODtTC )la n He l5ll Onrraa

Yl'II I. c6d020<:a·b I b9-4a0d-b987-d6b4S8968c2S

06JIBnEliHE lA 81,JJlOl!CEHA OOP"b'!KA (•c:pc,u 7)

0DHC3HHe Ha ODUHHTe:

II.2.13) H1u)1opMa� OTHOCHO cpeACTBB OT EBponeiiCKHJI C'hl03 061..UeCTBeeaTa nopssxa e BoB BJ)'b3Ka c npoeer n/wm nporpassa, <l>HHaacHpau/a CbC }.la D He� Cpe,ACTBa OT Esponeacsaa C'bl03 li,ueHTHcl>HKaUHR Ha npoexra:

II.2.14) }.lon'bJIHHTeJIHB HH<}lopM�:

P A3llF.JI II: Onacanae / 06oco6eua noamraa II.2) OnHcaime 1

11.2.1) HBHMeHOBaHHe: 2 I - ea rpyna Jin I .nel7icT aaura B'bpxy CCC 06oco6ena D03HUHJI NQ: 27 2

II.2.2) }.lon'bJIHHTCJIHH CPV KOAOBe 2 Ocaoaea CPV KO.A: 1 33690000 .Aon'bJlHHTeneu CPV KO.A: 1 2

II.2.3) MRCTO Ha H3Il'bJIHCHHe OcHOBHO M.IICTO Ha H3D'bJ11ieH11e: anTeKa Ha YMSAJI Eyprac" A,I:1 KO.A NUfS: 1 BG�41 II.2.4) 0DHC8Hfle Ha o6m;eCTBeuaTa nop'l»'IKa: (ecrecrso H KOJJH'leCTBO Ha crpOHTeJJHH pafiora, .UOCTaBKH HJJH YCJlYfH HJJH yxaaaane Ha DOTpe6HOCTH H H3HCKBaHIUI) 273Propafenone 150mgtabl 274Propafenone 300mgtabl 275Verapamil 120 mgret. tabl. 276Verapamil 40mgtabl. film ll.2.5) KpHTepHH aa e'b3.llaraue • 2 D KpHTepHii aa xasecrao - MMe: / Te)KeCT: 1 2 2°

D Kpnrepaa, cm.paaa c paaXO.AH - 11Me: / Texcecr: 1 2• � Lleaa -Texcecr: 21

0.2.11) HH<}lopMB.JniJI OTHOCHO o�e 0DQHH J.laO He� OaHCaHHe Ha ODUHHTe:

II.2.13) HH<}lopMB.JniJI oruoeno cpeACTBB OT EBponeiiCKKR C'hl03 Ofiutecraeaara nops-uca e Boe BJ)'b3Ka c npoexr H/wm nporpaaa, cJ>nnaHcupatt/a C'bC }.la D He� cpencraa OT Eaponeacxas C'bl03 11,ueHTHcl>HK3UHff Ha rrpoexra:

Il.2.14) }.lmn.JJHflTeJIHB HH<}lOpMBUH.R:

PA3llF.JI Il: Orraeaane / 06oco6eua noasmna II.2) Onacaane 1

II.2.1) Haasseaoaanae. 2

II - pa rpyna JID, .ne11CTBam111 B'bpxy CCC 06oco6ena D03HUHJI NQ: 2 8 2

11.2.2) }.lom,.1mHTeJIHH CPV KOAOee 2 Ocuoaea CPV KO)l: 1 33690000 .Aon'bJlHHTe.neH CPV xon: 1 2

YliJI c6d020ca-blb9-410d-b987-d6b458968c25

flapTHAI 06l!BJIEHHE 3A 81,JJJQ)l(EHA OOP'b'UCA (oq,c,u 7)

D.2.3) Macro Ha H3Jl'hJIBeHHe OcHOBHO MJICTO Ha H3ffbJTHem,e: an Te Ka Ha YMSAJl Byprac" A,U KO.A NUTS: 1 BG341 D.2.4) ORHcaHHe Ha o6�eC'l'BeHaTa DOJ>'l>'IK&: (ecrecrso H KOJJB'leCTBO Ha CTpOHTeJIHH pa6orn, JJ.OCTaBKH WIH YCJl)'rH HJ111 yxaaaaae Ha DOTpe6HOCTH 11 H311CKBamu1) 283Glyceryl trinitrate lmg/ml SOml anKOXOJleH pa3TBOpintravenous inf. 285Isosorbide dinitrate Smgtabl 286Ivabradine 5 mgtabl. film coated 287Ivabradine 7,5 mgtabl.film coated U.2.5) KpHTepHH aa B'b3.llara.He 1 2 O KpuTep11ii aa Ka'!eCTBo - l1Me: / Te>KeCT: 1 2 2° O KpHTepHH, CB'bp3aH c paaxona - l1Me: / Te)KeCT: 1 2° � Ilexa - Te>KeCT: 21

11.2.11) HHcf>opMBUHJI OTHOCHO ODUHHTe Omraa ,Zla O He� Onacaane Ha o�H11Te:

D.2.13) HHcf>opManHJI OT.ROCHO cpeACTB8 OT EepooeucKHJI C'hl03 06U1eCTse11aTa DOJYb'IKa e B1>B apssxa c npoexr e/HJJH nporpawa, cpHHaHCHpaH/a C'bC ,Zla O He� cpeJJ,CTBa OT Eaponeacxaa C'bJ03 l1JJ.eHTH<PHKaUHH Ha npoexra:

11,2,14) ,ZlOD'hJIHHTeJJHB HHcf>OpMfilO{JI!

P A3,[{F.JI II: Onncaane / 06oco6eHa noau.._HJI U.2) Onacanne 1

II.2.1) HBHMeuoeauHe: 2 VI - Ta rpyna Jl ll I .neYicTsami,i B'bpXy CCC 06oco6eHa ao3HUHH NQ: 32 2

II.2.2) ,Zlon'bJlllHTeJJHH CPV KOAOBe 2 Ocuoaeu CPV KOJJ.: 1 33690000 .[lon'bJIHHTe.neH CPV KOJJ.: 1 2

II.2.3) Mllero na H30'hJlHeHHe 0CROBHO MJICTO Ra H3D'bJIHeHHe: anTei<:a Ha YMSAJl Syprac A.Il KOJJ. NUTS:1 BG�41 II.2.4) Onncaasse Ha ofimecraeua'ra nop-snxa: (ecrecrso H KOJlH'leCTBo ea CTpOHTeJIHH pa60TH, AOCTaBKB HJJH YCJIYTH HJJH yxaaaane aa DOTpe6uOCTH H 113HCK8aHHH) 326Moxonidine 0. 4mgtabl. film II.2.5) KpHTepHH aa e'b3.llaraHe 1 2 O KpuTepHH sa xasecrao - l1Me: / Texcecr: 1 2 2° O Kparepaii, CB'bp3aH c pa3XOJJ.H - l1Me: / Texcecr: 1 2° 121 Ueea - Tescecr: 21

II.2.11) Bncf>opM8JlHJI OTHOCHO ODUHHTe Om,\HH ,Zla O He� Onacaaae Ha ODUHHTe:

U.2.13) HHcf>opM&J.OUI OTHOCHO cpeaeraa OT EupooeucKHJ1 C'hJ03 Ofimecrueaara DOJYb'IKa e B'bB apsaxa c npoexr 0/HJJH nporpassa, cpH11a11cHpa11/a C'bC ,Zla O He� cpeJJ,CTBa OT Esponeacxaa C'bJ03 11JJ.eHTH<PHK8UHH Ha npoexra:

YHfl c6d020ca-blb9-'la0d-b987-d6b4S896!c2.5 9

111.2.14) 110 ....... mrreaaa HH,j>OpMa,...,.,

P A3,llEJI II: Orracasrae / 06oco6eHa noamrna n.2) Onncamse 1

06!lBJ1EHHE 3A Bl,JJIOJKEHA DOP'b'IKA (oq,o•• 7)

Il.2.1) ffBHMCHOBa.HHC: 2

8JlOKep1'1 Ha KaJlU1'1eB1'1Te i<:aHaJ11'1 11 KOMCi1'1HaU1'11'1 06oco6eHa D03HUHJI NQ: 34 2

11.2.2) .l(OJI'h.llHHTCJIHH CPV KOAOBC 2

Ocaosea CPV KO.A: 1 33690000 )J.om,.nHHTeneH CPV KO.A: 1 2

11.2.3) M.RCTo ua H3D'hJIHCHHC 0CHOBHO MJICTO Ha H3D'b.11HeHHe: an Te Ka Ha YMBAJI Byprac NI KO.ll NUTS:1 BG'-tdl

II.2.4) 0JIHCBHHC HD o6m;eCTBCH8T8 nop'L'IKB: (ecrecrso H xonaxecrao Ha crpOHTeJIHH pafiora, .llOCTaBKH HJlH ycnyra HJIH yxaasane Ha DOTpe6HOCTH " H3HCKBaHHJ1) 346Felodipine Srngtabl 347Lercanidipine hydrochloride lOrngtabl. film

U.2.5) KpHTepHH aa B'b3./larB.He 1 2 D Kp11Tep110 aa xasecrao - MMe: / Tesceer: 1 2 2° O KpHTep11it, cespsaa c pasxona - 11Me: / Tescecr: 1 2° � Ileua - Te>1CeCT: 21

11.2.11) He4>opM�HJI OTHOCHO om.r;HHTC Onu11_11_ .l(a O He181

Onacaaae Ha OOUHHTe:

11.2.13) Du4>opM8�HJI OTHOCHO cpencrna OT EuponeHCKHJI C'LJ03

.l(a O He181 Ofimecraeaara nopsuxa e B'bB epsaxa c npoexr n/w1H nporpaaa, q>11HaacHpaH/a C'bC cpeaeraa OT Esponeacxaa C'bl03 l1,AeHTHq>11KauHJ1 Ha upoexra:

ll.2.14) .l(OJI'h.llHHTCJIH8 HH4>0pM8�:

PA3,llEJI II: Onncaane / Ofiocotieaa n03HI.\HJI Il 2) 0DHC8HHC 1

Il.2.1) ffBHMCHOBaHHC: 2

I - pa rpyna ACE 1'1HX1'!01'1TOP1'1 Otiocobeaa noaHUHJI NQ: 36 2

11.2.2) .l(On'bJIHHTe.1nfH CPV xonoae 2

Ocaosea CPV KO.A: 1 33690000 )J.Ort'b.llHHTeneu CPV KO.A: 1 2

11.2.3) M.RCTO Ha H3ll'hJIHCHHe

0CHOBHO MJICTO Ha B3D'b.11HeH11e: an Te Ka Ha YMBAJI Byprac A,n KO.A NUTS:1 BG341 Il.2.4) 0DHCBHHC Ha o6m;eCTBeH8T8 nop'h'IKB: (ecrecrso n KO.lll{qecrso Ha crpoarenua patiora, nocraaxa wn, ycrryra IUIH yxaasaae Ha norpetiaocra H H3HCKBaHHJ1) 369Ramipril Srng + Hydrochlorothiazidetabl 3610Trandolapril I Veraparnilcaps.

Y�ITT· c6d020ca·blb9"4a0d·b987·d6b4S8968c25 10

0611BJIEliliE 3A B'b3!10JKEHA OOP'b'U<.A (•cpc•• 7)

3611Trandolapril O.Smgcaps. 3612Trandolapril 2mgcaps. II.2.5) KpHTepHH 38 e'b3JlaraHe 1 2

O KpHTepHH aa xasecrao - MMe: / Te)KeCT: 1 2 2° O Kparepmi, CB'bp3aH c paaxona - liMe: / Texceer: 1 2° � Ileaa -Teacecr: 21

II.2.11) IIH«l>OPM8XUUI OTHOCHO ODJJ,HHTe Omraa .ll.aO Hei81 Onacaaae Ra onuaare:

II.2.13) HH4>opMau;HJ1 OTHOCHO CPCACTBa OT EsponeucKHJI C'bl03 06meCTBeHaTa DOp'b'IKa e B'bB apssxa c npoexr H/IUJH nporpaxa, <PHHaHCHpaH/a C'bC ,ll,a O Hei81 cpeacraa OT EaponeHCKHJI C'bl03 11.n,eHntcpHI<aQHR Ha npoexra:

Il.2.14) ,ll,OII"hJIHHTC.IJ.Ha HH«l>OpMa�:

P A3.[(EJI II: Onncaane / 06oco6eua no3Hl.\WI Il 2) 0llHC8HHe 1

II.2.1) Ha.HMeH0BaH11e: 2

II - pa rpyna ACE HHXMOJIITOpX Ofiocofieua no30q11J1 NQ: 37 2

II.2.2) ,ll,on'bJJHHTeJIH11 CPV xonoae 2

Ocxosea CPV KO.ll: 1 33690000 Zlomoraarenea CPV KO,ll: 1 2

II.2.3) MRCTo na H3n'bJJHeHHe 0CHOBHO MJICTO Ha H3D'bJ1HeHHe: an Te Ka Ha YMSAJl Byprac A,[\ KOP. NUTS:1 BG341

II.2.4) Ormcamte Ha o6�eCTBeHaTa nop'bqxa: (ecrecrso H KOJTH'leCTBO Ha CTpOHTeJIBH pa60TH, ,llOCTaBKH HJJH ycrryrn HJIH YKa3BaHe Ha DOTPe6HOCTH H 03HCKBaHIU1) 372Fosinopril lOmgtabl 374Moexipril 15 mgtabl.film coated 375Moexipril 7.5 mg tabl.film coated Il.2.5) KpHTepHH aa B'b3JlaraHe 1 2

O KpHTepHH sa xaxecrso - l1Me: / Te)KeCT: 1 2 2° O KpHTepHH, cB'bp3aH c pasxona - l1Me: / Tescecr: 1 2° � Ileaa -Tescecr: 21

II.2.11) HH4>opMa� OTHOCHO OIIl(HHTC Omraa .ll.aO Hei81 Ormcanae Ha onuaare:

II.2.13) HH«l>opMa� OTHOCHO cpeneraa OT Eeponeucl<HJI C'bl03 Otimecraeuara DOp'b'IKa e B'bB B)Yb3Ka c npoexr H/HJJH nporpaxa, cpHHaHCHpaR/a C'bC ,ll,a O Hei81 cpencrsa OT Eaponeacxaa C'bl03 11,ueHTH(pHKaQHJI Ha npoexra:

II.2.14) ,ll,on'l>JIBHTeJIHa HH4>opMau;HJ1:

YHn: c6d020ca·b I b9-4•0d·b987-d6b458968c25 II

P A3.l(FJI II: Onacauae / 06oco6eHa D03HJUIJI 11.2) 0DHC8HHe 1

06.RBJIEJfflE JA ll'l,JJJOJICEHA 001'1,4.l(A (1cpcHJ1 7)

11.2.1) HaHMeHOB8HHe: 2

,J:\111ypeTJ..1U Ofiocofieaa D03HUHR N2: 39 2

II.2.2) )'.(Oll'hJlHHTeJIHH CPV JCOAOBe 2

OcHoBeH CPV xon: 1 33690000 .Uon'bJJHHTe.neH CPV xon: 1 2

-- 11.2.3) MJICTO Ha H3Irh.11HeHHe 0CHOBHO MHCTO Ha H3D'bJJHeHHe: a n r e xa Ha YMBAJ1 Byprac AA KO.U NUTS: 1 BG341

ll.2.4) Ormcamre Ha o6m;eCTeeHaTa DOJ>'l,'1.Ka: (ecrecrso H KOnHtteCTBO Ha crpOHTeJIBH patiora, ,l{OCTaBKH HJJH yCJJyrH HnH yxaasaae Ha DOTpe6HOCTH H 1'13HCKBaHHJ!) 395Torasemide 10 mg tabl 396Torasemide 5 mgtabl II.2.5) KpHTepHH aa B'l>3Jlar8He 1 2

O KpHTepHH sa xasecrso - MMe: / Te*eCT: 1 2 2° O Kparepan, csspaau c pasxozra - l1Me: / Te*eCT: 1 2°

• � Ileaa - Texcecr: 21

11.2.11) Hu4>opMau;HJ1 OTHOCHO on�e OnuHH )'.(a0 He� Onacanae Ha onuaare:

II.2.13) BH4>opMa� o'raecao epeneraa OT EeponeiicKHJ1 C'l>J03 Ofiutecraeaara nopsxxa e B'bB spsasa c npoexr H/wrn nporpaaa, <j>HHaHcHpaH/a C'bC )'.(a0 He� cpeacrsa OT Eaponeacxaa C'bI03 H.nettn1<t>HKaJ.IHJ1 Ha npoexra:

ll.2.14) )'.(OD1..TIHHTeJlH8 HH4>opMau;HJ1:

PA3.l];FJI II: Orracamre / 06oco6eHa no3HJ.UUI Il.2) 0DHC8HHe 1

11.2.1) HaHMeHOBBHHe: 2 OpaJ1H1t1 aHT"1.QJ.1a6eTHJ..1 cpe.QcTea Ofiocofieaa D03HUIUI NQ: 47 2

ll.2.2) )'.(On'bJIHHTeJIHH CPV KOAOBe 2 OcHoBeH CPV xon: 1 33690000 .Uon'bJJRHTe.neH CPV xon; 1 2

II.2.3) Macro Ha H3D'bJIHeHHe 0CHOBHO M.IICTO Ha H3D'bJJHeHHe: anTe1<:a Ha YMBAJI Byprac A,J:\ KO,n NUTS: 1 BG341 II.2.4) ODHcaHHe Ha o6m;eCTBeHaTa nop'b'I.Ka: (eCTeCTBO H xonaxecrao Ha CTpOHTeJIHH pa60TH, nocraaxa WIH ycnyra HJJH yK83BaHe Ha OOTpe6eoCTH H 83HCKB8BHJ!) 4 7 9Si tagliptin, Metformin 50 mg/1000 mgtabl. film coated Il.2.5) KpHTepHH aa e'b3JlaraHe 1 2 O KpHTepmi sa xaxecrao - liMe: / Texcecr: 1 2 2° O Kpnrepaa, cespsaa c pasxona - 11Me: / Texcecr: 1 2° � UeHa -Te)KeCT: 21

11.2.11) H1ubODMau;HJI OTHOCHO omrnsrre

YHl'I: e6d020ca-blb9-4a0d·b987-d6b458968c2S 12

naJ)'tlfJle 06SIBJll'!Hlffi 3A B1,JJ10JKEHA nOP'b'IKA (1epcHx 7)

Onuaa .D:a LJ He� Onacaaae Ha OOUHHTe:

II.2.13) Hnct,opM� OTHOCHO cpe.11.CTBa OT EeponeHCKHJI C'l>I03 06lllCCTBCHaTa DOP,,\fKa e 81>8 BP,,3Ka c npoexr H/HJJH nporpava, q>HHaHCHpaH/a C'bC .n:a D He181 cpencraa OT Eaponeacsas C'bl03 H)leHTHq>HKaLIHJI Ha rrpoexra:

Il.2.14) ,ZXOD'hJIHltTCJl.Ha HHct,OpM�:

PA3,ll,FJI Il: Onucanue / 06oco6eua oo3H�HJI II.2) Onacanae 1

II.2.1) H8HMeHoe8HHe: 2 I - ea rpyna rm. no BJ11'1R aalllH KP'bBTa, Kp'bBOHOCH1'1Te C'b.OOBe 111 Mv1KpOU1'1pKyJ1aUHRTa 3a napeHTepanHo np111J1o)KeH111e Ofiocofieaa D03HUHH NQ: 50 2

II.2.2) ,ZXOD'hJIHHTC.JIHH CPV xonoae 2 Ocaoaen CPV KOA: 1 33690000 .l(o01>11HHTeneH CPV KO)l: 1 2

Il.2.3) MJICTO H8 H311'hJ1HCHHe OcuOBHO M11CTO aa H3trbllueu11e: an Te Ka Ha YMBAJJ Byprac A,[\ KO.A NUTS: l BG141

II.2.4) 0DHC8HHC ea o6�eCTBCH8T8 DOl)'b'IK8: (ecrecrao H xonasecrso aa CTpOHTeJlHH patiora, )lOCTaBKH HJIH ycnyra HJJH yxaasaae Ha DOTPC6HOCTH H H3HCKBaHHJ1) 502Nimodipine lOmg 50mlintravenous inf. II.2.5) KpHTepHH aa B'b3Jlar8He 1 2 D KpHTepHH aa xasecrao - MMe: / Tescecr: 1 2 2° D Kpurepafi, CB1>p3aH c pa3XOJlH - 11Me: / Tescecr: 1 2° � Ilena - Texcecr: 21

II.2.11) IIHct,opM� OTHOCHO OillOfHTe OnUHH .ZXa D He181 Onacanae Ha ODUITTfTe:

II.2.13) HHct,opMa� OTHOCHO cpeJJ.CTB8 OT EeponeiicKHJI C'l>I03 06mecreeuaTa nopusxa e B1>B spsaxa c npoexr H/wm nporpasra, q>HuaHcHpaH/a C'bC .ZXa D He181 cpencrsa OT Eaponeiicxaa C'bl03 H)lCHTHq>HKaUHJI Ha npoexra:

II .2.14) .D:on'b.llHHTC.JIBa HHct,OpMaI(HJI!

P A3.ll.FJI II: Onucanue / 06oco6eua D03H� U.2) 0IIHC8HHC 1

11,2,1) H8HMCHOB8HHe: 2 I - ea rpyna nn, nOBJ1HRBallll'1 Kp'bBTa, Kp'bBOHOCHJl!Te C'b.[lOBe l'1 Mlt!KpOU1'1PKYJ1aUHRTa 3a nepopaJ1HO np111J10)KeH111e 06oco6eua ao3HUHJI N2: 51 2

11.2.2) .D:on'b.llHHTCJIHH CPV xonoae 2 Ocaoaea CPV KOA: 1 33690000 ,llon'bllHHTeneu CPV KO)l: 1 2

YtUl e6d020ca·blb9-4t0d·b987-d6b4S8968c2S 13

06JffiJIEH»E 3A 81,JJIO)l(EHA noP'l,'-O<A (acpOlll 7)

II.2.3) MRcro ua H3D'hJIHeHHe 0CHOBBO MJICTO ea H3ffbJIHeHHe: anTeKa Ha YMSAJl Syprac xn KO.A NUTS:1 BG341 11.2.4) OnHcauue Ha o6�eCTBeuaTa DOJ>'b'IKB: (eCTeCTBo H KOJIH"leCTBO ea CTpOHTeJIHH pa6orn, .noCTaBJCB HJJH ycrryra HJJR yxaaaaae Ha no-rpe6BOCTH H H3HCKBaHIUI) 513Rivaroxaban 10 rngtabl.filrn coated 514Rivaroxaban 15 rngtabl.filrn coated D.2.5) KpHTepHH aa B'b3Jlar&He 1 2 O KpnTepHA aa xaxecrso - MMe: / Te>KeCT: 1 2 2° O Kparepua, csspaau c paaxoaa - MMe: / Te>KeCT: 1 2° 5a Ileaa - Te>KeCT: 21

U.2.11) Hncl>opMaJJ.HJI OTHOCHO O�HHTe Onuaa .l(a0 He� Onacauae ea ODJ.lHHTe:

II.2.13) llHcl>opMat(HJI OTHOCHO cpeneraa OT EeponeHCKIUI C'bl03 Ofiurecreeuara aop-L'IKa e BoB BP'b3Ka c npoeier u/wrn uporpasra, cpueaecHpae/a esc .l(a O He� cpencraa OT Eeponeiicxna C'bl03 11.neBTH<pHKaUHJI ea npoexra:

II.2.14) .l(oll'hJIHHTeJIHa HHcl>opM�HJI:

P A3,[{EJI II: Onncaasre / 06oco6eHa noamraa II.2) OOHcaHHe 1

II.2.1) HBHMeHOBBHHe: 2 II - pa rpyna nn, nOBJlll\.RBall.11'1 !<p'bBTa, Kp'bBOHOCHMTe C'b,IJ.OBe l'1

MMKpouMpKynauM.RTa 3a napeHTepanHo npV1J10lKeHJ.1e Otiocofieua nosauaa N2: 52 2

n.2.2) .l(orn.J1HHTeJIHH CPV xonoae 2 Ocaoaea CPV Ko.n: 1 33690000 .llon'bllHHTenee CPV xoa: 1 2

0.2.3) MJiCTO Ha H3D'bJlHeHHe OcHOBHO MllCTO Ha H30'b11HeHHe: an Te Ka Ha YMSAJl Byprac A.II KO.A NUI'S:1 BG341 0.2.4) OnHCBl:Ule Ha o6�eCTBeHaTa nop'l,111Ca: (ecrecrao H KOJlH'leCTBO ea crpOHTeJJHH pafiora, ,llOCTaBKH HJIH ycnyra 11.JUI YK3383He ea norpetiaoera 11 H3HCKB3HIUI) 521Alprostadil 20 mcgsol.inj. 524Alprostadil 500 rncg/1 rnlconcentrate for solution for infusion ll.2.5) KpHTepHH aa B'b3Jlaraue 1 2 O KpHTep11i% sa xasecrso - MMe: / Tescecr: 1 2 2° O KpHTepHH, csspaaa c pasxona - MMe: / Teacecr: 1 2° l5ll Ileaa -Texceer: 21

0.2.11) HHcl>opMat(HJl OTHOCHO O�HTe Onu11H .l(a O He� OnHcaH11e aa onuaare:

U.2.13) HHcl>opMa� OTHOCHO cpeneraa OT EeponeifcKHJ1 C'b103 Ofintecrseaara nopasxa e e'bn spsaxa c npoexr H/HJIH nporpassa, Q>HHattcupatt/a C'bC .l(a O He� cpencraa OT Esponekcxaa C'bl03 M.neeTH<pHK3UHll Ha npoexra:

14

P A3Jl.EJI II: Onncaane / 06oco6ena no3HIQIJI II.2) Onacanne 1

06mJJlllH11E 3A B'b3JIOlKEHA nOP'b'lKA (1q,c•• 7)

II.2.1) HaHMeHoe&HHe: 2 Vinpocetine 5mg 06oco6eHa D03Hl.lHJI NQ: 56 2

II.2.2) ,Uon'hJIHHTeJJ.HH CPV xoaoae 2 Ocaoaeu CPV xon: 1 33690000 ,l:\oa'bJIHHTeJJeH CPV xon: 1 2

II.2.3) MBcro Ha Han'bJIHeHHe 0CHOBHO MJICTO Ha H3Il"h11Hettt1e: anTeKa Ha YMBAJJ Syprac AA KO)l NlITS:1 BG341

II.2.4) Omscanae ea o6m.ecreeeaTa nop-sxxa. (ecrecrso B KOJIH'leCTBO ea CTpOHTeJJHH pa60TH, .UOCTaBKR Rllll ycnyra RJIH yxaaaane Ha DOTpe6HOCTH H H3HCKBaHW1) 562Human prothrombin complex 500 IUpowd. Inj. ll.2.5) KpHTepHH aa e'b3JlaraHe 1 2 D Kparepaa aa Ka'leCTBO - 11Me: / Te)KeCT: 1 2 2° D KpHTepRH, CB'bp3aB c pasxona - 11Me: / Texcecr: 1 2° � Ileaa - Te)KeCT: 21

Il.2.11) BHc):>OpM&l(HJI OTHOCHO O�HHTe Om(HH .Ua D He181 Onacaaae ea ODUHHTe:

II.2.13) BHcJ:>opMan;HJI OTHOCHO cpeaeraa OT EsponeiiclCHJI C'bl03 Otiuiecrseaara nopsxsa e B'bB apsaxa c npoexr u/Hl!H nporpassa, Q)HllaHCHpaH/a csc .Ua D Hel81 cpeacraa OT Eaponeiicxaa C'bl03 H.ueHTHQ)HKauHJI Ha npoexra:

11.2.14) .Uon'hJJHHTe./llla HHc):>OpM81.(HJI:

P A3Jl.EJI II: Onncaane / 06oco6ena 11030� II.2) OOHcaHHe 1

11.2.1) HaHMeHoeaKHe: 2 AHTJIIKOaryJ1aHTJII 06oco6etta ao3HUHJI NQ: 59 2

II.2.2) ,Uo1n,mnnen:HH CPV JCO,AOBe 2 Ocaoaea CPV Ko.1.1.: 1 33690000 .l(oo'bJIHHTeneH CPV xon: 1 2

II.2.3) Mscro Ha H31I'hJJHeHHe OcHOBHO MJICTO Ha H3D'bJIHeH11e: C50JlHl.1YHa anTeKa KO.U NtITS:1 BG�41 II.2.4) Omrcaane Ha ofimecraerrara DOp'b'IIC&: (ecrecrso H KOJIH'leCTBO Ha CTpOHTeJJHH pa6orn, )lOCTaBKH HJIH yCJ1yrH HJJH yxaasaae Ha DOTpe6110CTH 11 H3HCKBaHRJ1) 592Bemiparin solution for injection 2500 IU anti-Xa/0,2 mlsol.inj. II.2.5) KpHTepHH aa B'b3Jl&raHe 1 2 n KpHTepu11 aa xasecrao - 11Me: I Te)KeCT: 1 2 2°

Ytlfl e6d020ca·b I b9-4a0d·b987-d6b4S8968o2S IS

napTIIIII 06ruJJIEH111! 3A B1>3n0)1(£HA nOP'b'-IKA (•CJ>••• 7)

D KpHTepHH, cespaaa c pa3XO.LlH - 11Me: / Texcecr: 1 2° � Ileaa - Tescecr: 21

II.2.11) Hucl>opM81UIH OTHOcHo OJUOI-HTe 001,IHH .llaD He� Onacauae aa onuasrre:

II.2.13) Hecl>opMa.I(HJI ornocne cpeacraa OT EepoaeiicKHJ1 C'hJ03 06weCTBeHaTa DOJYb'lKa e B'bB BJYb3Ka c npoexr e/wrn nporpaaa, <t>enaecHpaH/a csc )la D He� cpeaersa OT Eaponeacxaa Cbl03 li,neHTH<l>HKaUHJI Ha npoexra:

Il.2.14) )lOD"h.llHHTeJIHa HJJcl>OpMa.I(HJI:

P A3.l).EJI II: Onacauae / 06oco6eaa noamraa II.2) Onaeaaae 1

Il.2.1) HaHMeHOBaHHe: 2 Ma 1<:pon11..Qv1 Ofiocofieaa no3HUHJI NQ: 97 2

n.2.2) )lOD"hJIHHTeJIHH CPV KOAOBe 2 OcHOl!eH CPV Ko.n: 1 33690000 ,Uon'bJIHwreneu CPV xon: 1 2

II.2.3) MJiCTO Ha H3D"hJIHCHHe OCHOBHO MJICTO Ha H3ll'bJIHeHHe: 80IIHl1YHa an Te Ka KO.It NUTS:l BG'ldl II.2.4) OOHcaHHC Ha o6�eCTBCHaTa DOp'h'IJUl: (ecrecrso H KOJIH'leCTBo Ha c-rpOHTeJIHH pa60TH, ziocraexa HJlH YCJiyrH HJIH yxaasaae Ha nOTpe6HOC.''l'H H H3HCKBaHrui) 972Clarithromycin 125mg/5ml 60mlgran. 974Clarithromycin 250mgtabl. film II.2.5) KpHTepHH aa B'h3Jl8l'aHe 1 2 D Kparepaa aa xaxecrao - l1Me: / Tescecr: 1 2 2° D KpHTepmi, csspaan c pa3XO.LlH - 11Me: / Tescecr: 1 2° � Ileaa -Tescecr: 21

II.2.11) Hecl>opMa.I(HJI OTHOCHO O�HHTe 0DUHH )la D He� Onacaaae Ha ODUHHTe:

II.2.13) HHcl>opMa� OTHOCHO cpeACTBB OT EepoaeiicKHJI C'hl03 Ofiuiecraeuara nop'b'lKa e H'bB apsaxa c npoexr u/HJJH nporpasia, q>HeaHcHpaH/a esc .lla D He� cpencrsa OT Eaponeacxaa Cbl03 11JleHTH<l>HKal,IHJI Ha npoexra:

Il.2.14) )lOD'bJIHHTeJIHB HHcl>OpMa.I(HJI:

PA3.l].EJI II: Onacaane / 06oco6eaa noaHD;HJI Il.2) 01IHCBHHC 1

Il.2.1) HBHMeHOBBHHe: 2 I - Ba rpyna O�TaIIOMOrl1YHl1 nn 06oco6eHa n03H UHR NQ: 10 1 2

Il.2.2) .lloO'h.llHHTeJIHH CPV KOAOBe 2

YHll c6d020ca·blb9-4o0d·.b987-d6b4S8968c2S 16

napnt.aa: 06J!BJIEHKE JA 81,3JJOJKEHA noP'b'IKA (aepCH• 7)

Ocaosea CPV Ko,A: 1 33690000 ,UoIThJlHHTeneH CPV KO.A: 1 2

ll.2.3) MRcro Ha uan'hJIHeHHe 0CHOBHO MJICTO Ha H3ITbJIBeH11e: 60J1HJl!YHa an Te Ka KO.A NUTS: 1 BG341

II.2.4) Omscarrne Ha o6�eCI'BeHaTa nop'b'IKa: (ecrecrso 11 KOJlH<leCTBO Ha CTp011TeJ1HH pa60TH, ,AOCTaBKH HJlH ycnyrn HJ111 YKa3BaHe Ha UOTPe6HOCTH 11 H3HCKDamU1)

1011Brinzolamide 1% 5mleye drops 1014Timolol 0.5% Smldrops eye 1016Tobramycin 0.3%/Dexamethasone 0 .1% Smldrops H.a.g) KpHTepHH aa e'b3.llaraHe t 2 O KpinepHli aa Kaqecrso - HMe: / Texcecr: 1 2 2° O KpHTepHH, CB'I,p3aH c pa3XO.L\B - HMe: / Te)KeCT: 1 2° i2I Ileaa - Te)KeCT: 21

11.2.11) lbul>opM� OTHOCHO OnqHHTe OaQHH AaO He� OnHcaH11e Ha OllQHHTe:

ll.2.13) Hu4>opM� OTHOCHO epeneraa OT Eeponeit:ckHJI C'bl03 06IQeCTBeHaTa ll0JYl>qJ(8 e B'bB apsaxa c npoexr H/HJ1H nporpaxa, q>HHaHCHpaH/a C'bC AaO He� cpencrsa OT Esponeacxas C'bI03 11,AeHTHq>HKaQHJI Ha npoexra:

11.2.4) )J;Oll'l,,JIHHTe.TIHa HH4>opMa�HJ1:

PA3,ll;F.JI II: Orracanne / 06oco6eua noamraa 11.2) 0DHC8HHe 1

11.2.1) HaHMeHOB8HHe: 2

IV - Ta rpyna npOTJl!BOB�3nan111TeJ1HJ11, 06e36onHaam111 JI! TeMnepaTyponoH111�aaam111 Otiocofieua no3HQHJI NQ: 114 2

11.2.2) ]lOll'bJJHHTe.JJHH CPV KOAOBe 2

OcHOBeH CPV KO.A: 1 33690000 .Uon'bJlHHTeJleH CPV KO.A: 1 2

ll.2.3) MRcro na H3n'hJIHeHHe 0CHOBHO MJICTO Ha H3D'bJ1HeHHe: 60J1HJl!YHa an Te Ka KO.LI NUTS:1 BG341

II.2.4) Onsrcarrae Ha o6�eCI'BeHaTa nop'b'IKa: (ecrecrso H KOJlH<leCTBO Ha CTpOHTe.TlHH pa60TH, ,AOCTaBKH HJlH ycnyra HJlH YK83BaHe Ha D0Tpe6HOCTH H H3HCKBaHID!)

114 3Allopurinol lOOmgtabl ll.2.5) KpHTepHH aa B'b3Jlaraue 1 2

O KpHTepHH aa xasecrao - MMe: / Texcecr: 1 2 2° O Kpurepaii, caspaaa c pasxozra - MMe: / Te)KeCT: 1 2° 121 Ileaa - Texcecr: 21

II.2.11) HH4>opM� OTHOCHO omnoere Onuaa AaO He� 00HC8HHe Ha OOQHHTe:

II.2.13) HB4>opM�.R OTHOCHO cpeneraa OT Eeponesicaaa C'bl03 Ofiureeraeuara uop-ssxa e B'bB ep'b3Ka c npoeier H/HJ111 nporpassa, q>HHaHCHpatt/a C'bC .UaO He� cpeacraa OT Bsponeacxas C'bJ03 H.AeHTHq>HK8QHJI Ha npoexra:

YHfl: e6d020ca-blb9-4a0d·b987-<16b4S8968c25 17

naJ)THJII'.

111.2.14) /lon,.,.HHTe,ma �,i,opM._,.,

PA3�F..71 ll: Onucauue / 06oco6eea noanuaa

06JIBJI.BHJ,!E JA 81,JJJQ)l(EHA 110P'h'lKA (acpctt• 7)

II.2) 0rrHC8HHe t

II.2.1) HaHMeuoeaHue: 2 VII - Ma rpyna nn, .nei1CTBaWl'1 B'bpxy CCC Otiocofiena noaauaa NQ: 116 2

Il.2.2) .Uon'hJIHHTeJUIH CPV KOAOBe 2 Ocaoaeu CPV xon: 1 33690000 ,Uo01,.11H11:Te.11ee CPV xoa: 1 2

II.2.3) MJICTO Ha H3rr&JIHeHHe 0CHOBHO MR.CTO Ha H3D'J,J1HeHHe: BOJ1Hl'14Ha an Te Ka KO.A NUTS:1 BG�41 11.2.4) Onncanne na o6meCTBeeaTa nop'snxa: (ecrecrao H KOJlH"leCTBO Ra CTpOHTeJTBH pafiorn, .AOCTaBKH HJIH ycnyra IUIH yxasaaae Ha DOTpe6HOCTII H H3HCKBaHW!) 1163Glyceryl trinitrate 0.4 mg/dosespray II.2.5) KpHTepHH aa B'b3JlaraHe 1 2 O KpHTepeii aa xasecrac - 11Me: / Tesceer: 1 2 2° O KpHTeplrli, caspaaa c paaxona - 11Me: / Tescecr: 1 2° Isa l.(eHa - Te)KeCT: 21

11.2.11) lbul>opMa� OTHOCHO Oill.OIJITC Oau11:11: .Ua O He181 OCUlcaHHe Ha ODUHHTe:

II.2.13) HH4>opMa� oruocao cpeACTBB OT EeponeHcKHJI C'hl03 Ofiurecraeaara nopsnxa e B'bB BJYb3Ka c npoexr 11:/H.1111: rrporpaaa, 4>11:11aucHpaH/a csc .Ua O He181 cpencraa OT Esponeacxaa C'bl03 11.a.eHTHQ>HKauHJI Ha npoexra:

Il.2.14) ,UOil'bJIHflTeJlB8 H-"4>0pMaJ.(HJI:

P A3�F..71 II: Onaeanae / 06oco6eea noamraa 11.2) OrmC8H_He 1

Il.2.1) HBHMeHOBBHHe: 2 AAT1'1aCMaTJ(!YHl'1 .nn 06oco6etta D03HUHJI N2: 119 2

II.2.2) ,UOil"h.JlHHTCJIHH CPV KO,!l;OBC 2 Ocaosen CPV xon: 1 33690000 ,Uoa'b/lHHTMeH CPV KOA: 1 2

ll.2.3) MJicro ua HaD'bJIHeHHe OcHOBHO MHCTO Ha H30'b/1HeHHe: 80JlHJIIYHa an Te Ka KOA NUTS:l BG-:t,11 II.2.4) 0UHC8H_ffe ua ofimeeraena'ra DOp'b'lK&: (ecrecrao H KOJlH"leCTBO ea CTPOHTMHH pa60TH, ,llOCTaBKH H.ITH ycnyru HJIH }'K33BaHe Ha 00Tpe6HOCTH H H3HCK13aHHJ1) 1191Aminophylline lOOmgtabl. film

II.2.5) KpHTepuH 38 B'b3JJ8TaHe 1 2 n KDHTeDHH 33 Ka"leCTBO - I-I.Me: / Texcecr: 1 2 2°

YHrJ c6d020ca·b lb9-4a0d·b987-d6b4S8968c2S 18

06.ffi3JlEHHE 3A B'b3JIOJKEHA CTQP1,4J<A (scpc•• 7)

D Kpsrrepaa, cespaaa c pasxozra - 11:Me: / Tesceer: 1 2° 121 Ileaa - Tescecr: 21

Il.2.11) HH(}>OpMRU;HJI OTBOCHO O�HTe OOUHH ,Aa D He181 Onacaaae Ha onuanre:

II.2.13) HH(}>opMau;HJI ornocao cpeacraa OT EBponeiiCKHJJ cr.roa Otiurecrseaara nopssxa e B'bB spsaxa c npoexr u/wm nporpasra, <lnlHaHcHpaH/a C'bC ,Aa D He181 cpeacraa or Eaponeacxaa C'bl03 li.L1eHTH<PHKaUHJ1 Ha npoexra:

Il.2.14) ,llOD'h.llHHTeJIHa HH(}>OpMRU;HJI:

PA3)lFJI II: Orracamse / 06oco6eaa noamma II 2) ODHcaJIHe 1 . 11.2.1) HaHMeHOBaHHe: 2 I - Ba rpyna aHT!l!TYC!l!BHM nn 06oco6eea aoaHQHJI NQ: 120 2

U.2.2) ,Aon'bJIHHTeJJHH CPV KOAOBe 2 Ocaoaea CPV KO,[.\: 1 33690000 ,Uoll'bJlHHTenee CPV KO,[.\: 1 2

Il.2.3) MJICTO Ha H3D'hJIHeHHe 0CHOBBO MJICTO ea H3D'bJIHeBHe: 80J1H1'1YHa an Te Ka KO.A NUTS:1 BG341 Il.2.4) Omscaane Ha o6m;eCTBeuaTa nop's=nca: (ecrecrso H KOJJH'feCTBO Ha CTpOliTeJJHH pa60TH, ,llOCTaBKH HJJll ycnyra HJIH yxaasaae Ha OOTpe6HOCTH H H3HCKBaerui) 1204Potassium guaiacolsufonate 170mlsyr. II.2.5) KpHTepHH aa B'b3.llaraue 1 2 D Kparepan aa Ka4eCTBo - 11:Me: / Texceer: 1 2 2° D Kparepnji, cespaaa c paaxozia - lilMe: / Tescecr: 1 2° 121 Ileua - Texcecr: 21

11.2.11) HH(}>opMRU;HJI OTHOCHO orrmrsrre Om.{HH ,Aa D He181 Onacaaae ea omraare:

Il.2.13) HH(}>opMRU;HJI ornocao cpeztcraa OT EBponeiicKH.J1 cr.ioa Ofimecraeaara DOp'b'IKa e B'bB apsaxa c npoexr H/HJTH nporpaxa, <PHHaHCHpaR/a C'bC ,Aa D He181 cpencrsa OT EepoaeHCKIUI C'bl03 Jil,[.leHTHcp1c1KauHJ1 ea npoexra:

Il.2.14) ,llOD''l,JIHHTeJJHa HH(}>OpMRU;HJI:

P A3)lFJI II: Ouacaaue / 06oco6eaa n03HJOI.JI

II.2) Onsscansre 1

II.2.1) HaHMeeoeaBHe: 2 v - Ta rpyna aHT1'1!1!H�eKU!l!03Hlll nn Ofiocofieaa aoaH�HJI NQ: 133 2

ll.2.2) ,Aoo'hJIHHTeJIBH CPV xonoae 2 Ocnosea CPV KO.LI: 1 33 690000

YHn. c6d020ca-blb9-4a0d-b987-d6b4S8%8c2S 19

06$1BJlEtOIE 3A Bl,lJIOJKEHA ll0P'h4JCA (IICp<K• 7)

.llorrb11HBTe.r1eH CPV KO.LI: 1 2

D.2.3) MJtcro ea H3n'bJleeHHe 0CHOBHO MJICTO Ha H30'bJIHeHHe: So11H1t1YHa anTei<:a KO.LI NlITS: 1 BG341 ll.2.4) Onncamre ea o6m,eCTBeeaTa nop-ssnca: (eCTeC'l'.BO H KOlJl{qeCTBO Ha crpOHTeJIHH pa60TH, ,LIOCT8BKH HJJH ycnyrn HJJH YKa3BaHe Ha 00Tpe6HOCTH H H3HCKBaRHH) 1333Ceftibuten 400mgcaps. 1335Ertapenem 1 gpowd. inf. Il.2.5) KpHTepHH aa B'b3JlaraHe 1 2 O Kp1nepHH sa xaxecrao - l1Me: / Te)KeCT: 1 2 2° O KpHTepHH, CB1>p3aH c paaxona - l1Me: / Te>KeCT: 1 2° � Ileaa - Tescecr: 21

11.2.11) Hu4>opM8l{HJI OTHOCHO omrmere Onuaa .D:aO He� Onacaaae Ha onnaare:

ll.2.13) He4>opMaD.HJ1 OTHOCHO cpeneraa OT EeponeucKHH C'bJ03 06meCTBeHaTa DOp-b'IKa e B'bB BP'b3Ka c npoexr H/HJJH nporpaaa, Q)HHaHCRpaH/a C'bC .D:aO He� cpe,LICTBa OT Eaponeiicxaa C'bJ03 l1,lleHTHQ)HKaUHJl Ha npoexra:

11.2.14) .D:oll'bJIHHTeJIHa He4>opMatQU1:

PA3AEJI II: Onucaaue / 06oco6eea noaHIJ;HJI 11.2) OnHCBHHe 1

11.2.1) HaHMeHOBBHHe: 2 AMOi<:ClilLU1111"1H f;1 i<:OMOY1Hau.111111 3a nepopa11Ha ynoTpeCa Ofiocofiena no3HUHR NQ: 135 2

Il.2.2) .D:on'bJIHHTCJJHH CPV xonone 2

Ocaoaeu CPV xon: 1 33690000 .llon'bJIHHTeneR CPV KOA: 1 2

Il.2.3) MJICTO HB H3ll'bJlHCHHe 0CROBHO MHCTO Ha H30'bJIHeHHe: SOJJHli!YHa arrne xa xon NlITS: 1 BG341 U.2.4) OnHcBHHe na ofimecraeua'ra nop'b'IKa: (ecrecrso H KOlJH'leCTBO Ha CTpOHTeJIHH pa60TH, ,llOCTaBKH HJIH ycnyra HJlH YKa3BaHe Ha nOTpe6HOCTH H H3HCKBaHHR) 1354amoxicilline+acidum clavulanicum 375mgtabl U.2.5) KpHTepHH aa e'b3JlaraHe 1 2 O KpHTepHH aa Ka'!eCTBO - l1Me: / Te)KeCT: 1 2 2° D KpHTepHH, cespaaa c paaxonn - l1Me: / Teacecr: 1 2° � Ileaa - Tesceer: 21

11.2.u) Hu4>opM81..{.HJI OTHOCHO OOJ..{KHTe .D:aO He� Om\HH

Onacaaae Ha ODUHHTe:

U.2.13) H.n4>opM8l{HJI OTHOCHO cpeACTBB OT EeponeucKHJI C'bl03 .AaO He� Ofimecreeuara DOp-b'IKa e B'bB BP'b3Ka c npoexr H/HJJH nporpasra, Q)HHaHcupaH/a C'bC

cpencrsa OT Eaponekcxua C'bl03 11.neRTH<l>HKaUHH Ha npoexra:

YHII c6d020ca·b I b9-4.od-b9S7-d6b4S8968as 20

06JlB11EH11E 3A 81,3.JlOJKEHA nOP'b4KA (•epctt• 7)

111.2.14) .llom.mune,n,a HRc)>OpMa""'"

PA3.D;EJI II: Onacaaae / 06oco6eHa noaarraa II.2) OnHcaHHe t II.2.1) HaHMeuoeaHHe: 2

II - pa rpyna Oq>TaJlOMOI'WJHJ:1 nn Ofiocofieua D03Hl.lWl NQ: 137 2

II.2.2) Aon'bJIHHTeJJHH CPV xonone 2 OcHoBeR CPV xon; 1 33690000 .l{om,nHHTeneH CPV 1<0.u: 1 2

II.2.3) MRcro aa uao'bJIHeuue 0CHOBHO MJICTO Ra H3D1,JJHeHHe: 60J1HY1YHa anTeKa KO.U NUTS: 1 BG"!Lll 11.2.4) 0DHcaHHe Ha ofimecraerrara DOJ>'b'IKa: (ecrecrso H KOJlH'leCTBO Ha C'rpOHTeJ1BH pa60TH, ,UOCTaBlCH HJlH ycnyra HJlH yxaasaue Ha UOTpe6HOCTH H H3HCKBaHID1) 1374Diclofenac 1 mg/ml - 10 ml drops eye 1379Hydrocortison cum chloramphenicol, Hydrocortisone acetate 5 mg/g /Chloramphenicol 2 mg/goint eye ll.2.5) KpHTepHH aa e'b3.llar8He 1 2

D Kp»TepHii aa xaxecrso - MMe: / Texcecr: 1 2 2° D Kparepaa, CB'bp3aH c pasxozra - MMe: / Tescecr: 1 2° i2i Ileua - Tescecr: 21

II.2.11) lhul>OpMaJOUI OTHOCHO onmorre 0DQHH Aa D He181 Onacaaae Ha onuaure:

II.2.13) HH4>opMaqKR OTHOCHO cpeaeraa OT EBpone:ncKH.B C'hJ03 Ofimecraeuara nopsvxa e B'bB spsaxa c npoexr H/wrn nporpaaa, qnrnaHcHpaH/a csc Aa D He181 cpencrsa OT Eaponeacxaa C'bl03 11.ueHTHq>HKaQwi ea npoexra:

U.2.14) Aoll'bJIHHTeJJHa HH4>opM81.(KR:

P A3.D;EJI II: Onacanne / 06oco6eHa noasnma Il 2) OOHcaHHe 1

II.2.1) HaHMeHOBaH.He: 2

II - pa rpyna AepMaTOJJOI'JIIYHJ.1 cpeACTBa Ofiocofieaa D03HQHJI NQ: 140 2

II.2.2) Aon'bJIHHTeJIHH CPV xonoae 2 OcHoBeH CPV KO.A: 1 33690000 .l{OO'hlIHHTenee CPV 1<0.u: 1 2

II.2.3) MRcro Ha uao'bJIHeHHe 0CHOBBO MJICTO Ra H3U1,JlHeHHe: 60JJHJ.14Ha anTeK:a KO.A NUTS:1 BG341 U.2.4) 0DHcaHHe Ha ofimecraerrara nop'b10(8: (ecrecrso H KOJllf'leCTBO Ha CTpOHTeJlBR pafiorn, ,UOCTaBKH HJlH ycrryra HJlJ,f yxaasaae Ha DOTpe6HOCTH H H3HCKBaHW!) 1409Betamethasone, Clotrimazole, Gentamicin 0,5 mg/10 mg/1 mg/g - 15 g

vim e6d020ca-blb9-4a0d-b987-d6b4S8968c2S 21

06JIBJIEHHE JA 81,lJIOJICEHA nQPl,\fJCA (oepcu• 7)

cream II.2.5) KpHTepHH aa e'b3.llaraHe 1 2 O Kparepail sa xasecrao - liMe: / TC)KeCT: 1 2 2° O Kparepaa, caspaan c pasxona - liMe: / Teacecr: 1 2° r2i Ileaa -Te)KeCT: 21

II.2.11) HH<l>OpM� OTHOCHO omnnrre Onuaa .n:aO He� Orracaaae Ha O�RHTe:

II.2.13) HH<l>opM� OTHOCHO cpeneraa OT Eaponencxaa c1>1oa Otimecrseaara nop'ssxa e B'hB spssxa c npoexr H/wrn nporpassa, q>HHaHCHpaH/a csc .ll:a O He� cpeztcrsa OT Eaponeacxaa C'hl03 I1,11,eHTHqmxao.FU1 Ha npoexra:

II.2.14) .ll:oD'r,JIHHTeJIHa HH<l>opM�:

P ��E.71 II: Omrcaane / 06oco6eua noamraa II 2) OnHcaHue t . 11.2.1) HaHMeHOBBHHe: 2 II - pa rpyna aHTYl,[\OTYI Ofiocofiena noaHUWI NQ: 143 2

II.2.2) .n:on'hJIHHTeJIHH CPV KOAOee 2

0CHOBCH CPV KO,D,: 1 33690000 .Uom,.11HHTeneH CPV xo,11,: 1 2

11.2.3) MHcro Ha H3Il'hJIHeHHe OcHOBHO MJICTO Ha l13IlbJTRCHHe: 80J1HYIYHa an Te Ka K0,11, NUTS: 1 BG341 Il.2.4) Orracaane Ha o6m;ecreeaaTa nop'h'IKa: (ecrecrso ff KO.IJKqecreo ea CTpOHTeJlHH pafiora, ,11,0CTaBKH HJlH ycnyru HJlH ysaasaue Ha DOTPe6HOCTH H H3HCKBaHFU1) 1431Carbo activatuspulv. 1432Carbo activatustabl 11.2.5) KpHTepHH aa B'b3JlarBHe 1 2 O KpHTepHH sa xasecrso - liMe: / Te)KeCT: 1 2 2° D Kp1nepKH, CB'bp3aH c paaxozm - 11Me: / TeJKeCT: 1 2° 121 Ueaa -Tescecr: 21

Il.2.11) HH<l>OpM�JI OTHOCHO O�HHTe Oniraa .n:a O He� Onncaune Ha onuaare:

Il.2.13) IIH<l>opM� o'rnocao cpenerna OT Esponencxna C'bJOa 06�eCTBeHaTa nopssxa e ll'hB BP'b3Ka c npoexr n/rura uporpasia, $HHaHCHpatt/a C'hC .n:aO He� cpenersa OT EaponeiiCKWI C'hIOa l1,11,eHT11$H1<ao,HJ1 aa npoexra:

Il.2.14) .ll:OD'hJIHHTeJIHa HHc}>OpM3lUUI:

YHfl: o6d020co-b I b9-4a0d-b987 -d6b4S8968c25 22

nap,- .... a; 06RBJIEHl1E 3A 01>3J10JKEHA nOPl,'IKA (upc ... 7)

PA3,UF.JI II: Ormeaane / 06oco6ena II03Hl(HJI

II.2) OnucaHHe 1

II.2.1) Ha11MeHoeaHHe: 2

II - pa rpyna aHT1'1,[IOTL1 Ofiocofieua no3HUHJI NQ: 14 6 2

II.2.2) J(on'hJ.UIHTeJJHH CPV xonoae 2

Ocaoeea CPV KO.I{: 1 33690000 .l(om,JJHHTeneH CPV xozr: 1 2

II.2.3) MJicro na H311'b.71HeBHe 0CHOBHO M.IICTO Ha H30'bJJHeHRe: SoJJHY1YHa an Te Ka KOA NUTS: 1 BG341 II.2.4) 011JfcaHHe Ha ofimecraerrara DOl)'h'lKa: (ecrecrao a KOJJK'leCTBO Ha CTpOHTeJlHH pa60TH, .llOCTaBKH HJIH YCJl)'l'H 11.11H YKa3BaHe Ha nOTpe6HOCTR H H3HCKBaHIDI) 1461Tranexamic acid 100 mg/ml 10 mlsol.inj. II.2.5) KpHTepHH aa B'l,3Jlaraue 1 2

D Kparepafi 3a Ka"leCTao - MMe: / Te)KeCT: 1 2 2° D Kparepati, CB'bp3aH c pa3XOAH - MMe: / T(!)l(eCT: 1 2° l5a Ileua - Te)KeCT: 21

II.2.11) lbu)>0pM� OTBOCHO Olll(HHTe OnuHH JJ:aD He� Onacauae Ha OUUHHTe:

ll.2.13) IIBc)>opM� OTHOCHO cpezrcraa OT EeponeucKHB C'I,J03 06�eCTBeHaTa nop'sxxa e B1>B spsaxa c npoexr u/11.11H nporpaxa, q>HHaHCHpaH/a CbC JJ:aD He� cpeacraa OT Eeponeacxas C'bJ03 11.lleHTHcpm<aUIUI Ha npoeicra:

II.2.14) J(OD'hJIHHTeJIHa HHc)>OpMa�:

P A3,UF.JI II: Omrcansse / 06oco6eua 11oaa�11 II 2) OnHCBBHe 1 . II.2.1) HBHMeHoeauue: 2

BJJOKep1,1 Ha aHI'l'10TeH31'1H II - peuenTopi1Te 06oco6eHa no31n\H.11 NQ: 38 2

II.2.2) J(on'bJJHHTeJJHH CPV KOAOBe 2

OcHoBeH CPV xon: 1 33690000 .l(om,JJHHTeJleH CPV xon: 1 2

II.2.3) MJICTO ea H3D'hJIHeHHe OcHOBHO Ml!CTO Ha H3ll'bJJHeHHe: OOJJHl'1YHa an Te Ka xon NUTS: 1 BG341 II.2.4) Onacanne Ha o6�eCTBeHaTa nop-sxxa: (eCTeCTBO H KOJJKCteCTBO ea CTpOHTeJlHH pa60TH, .llOCTaBKH HJlH YCJJ)'T'H HJlH yxaasaae Ha ll0Tpe6HOCTH H H3HCKBaHHJ1) 384Irbesartan 150 mgtabl.film coated 385Irbesartan 300 mgtabl.film coated 387Telmisartan 80mgtabl II.2.5) KpHTepHH aa B'l>3Jlaraue 1 2 D KpHTepHH sa xasecrao - 11Me: / Teacecr: 1 2 2° D KpHTepHii, cm.paan c pasxona - 11Me: / Texcecr: 1 2°

.121 Ileua - Tescecr: 21

YHn: e6d020ca·b I b9-4a0d,b987 -d6b458968c2S 23

fiaJJ'Ol'I& 06RBJIEH.J1E 3A 81>3JIQ)l(EHA nOP1.4KA (aepckJI 7)

II.2.11) HB<t>opM� OTHOCHO omrmere Onu,HH .naO He� Onacaxae ea om-1H11Te:

ll.2.13) HH<l>opMa�HJI OTHOCHO cpeneraa OT EeponeiicKHJI CI,J03 Otiiuecraeaara nOJ)'b'IKa e rn,e BJ>'b3Ka c npoexr H/wre nporpaxa, cpHHaHcHpae/a C'bC .naO He� cpeJJ.CTBa OT Esponeacsaa C'bJ03 11AeHTH$HKaU.H.R ea npoejcra:

ll.2.14) J:{OD'bJIHHTeJIH8 HH<l>OpM&qKR:

PA3,UFJI II: Onacanue / 06oco6eua noamraa 11.2) Onncaane 1

11.2.1) HBHMeHOB8HHe: 2

Ma 1q:>om1)l1-1 06oco6eea no3Hl.(IDI NQ: 97 2

II.2.2) .l{on'LJIHHTeJUIH CPV KOAOBe 2

Ocsoeea CPV KOJJ.: 1 33690000 }loo'h.1lH11Tenee CPV KOJJ.: 1 2

II.2.3) MJICTo ua H3D'bJJHeHHe 0CHOBHO MJICTO ea B31J'h1JReHHe: 60J1HJ.1YHa anTei<:a KOJJ. NUTS: l BG341

II.2.4) Omscanae Ha o6�eCTBeeaTa nop'hqKa: (ecrecrno H KOJllftleCTBO Ha CTpOHTeJJHH pafiora, JJ.OCTaBKH HJIH ycrryra HJUI yxaaaaxe Ha DOTpe6eOCTH H H3HCKBaBHJI) 976Clarithromycin 500mgpowd. inj. 977Azithromycin 500mgpowder for solution for infusion ll.2.5) KpHTepHH aa B'b3JlaraHe 1 2

D KpHTepHH aa xaxecrac - l1Me: / Teseecr: 1 2 2° D Kp11TepHu, csspaaa c pa3XOJJ.H - 11Me: / Texceer: 1 2° � Ileua - Te>KeCT: 21

II.2.11) HH<l>opM&qKR OTHOCHO OD�HTe Onu,HH .naO He� Onacaaae ea ODU.HHTe:

ll.2.13) Hu<t>opMB.l{HJI OTHOCHO cpeACTBB OT EeponeHCKHJI C'1,J03 Ofimecraeaara nOJ)'b'IKa e rn,e BJ)'b3Ka c npoexr H/JIIJIB nporpaxra, <l>HHaHCHpaH/a csc .naO He� cpeJJ.CTBa OT Eaponeacxus C'bJ03 11JJ.eHTHQ)KK81J,HJI Ha npoexra:

ll.2.14) J:{OD'bJJHHTeJJH8 HH<l>OpM&nH.R:

PA3.UFJI II: Onucauue / 06oco6eua n03HUHB

II.2) ODHcanHe 1

U.2.1) HaHMCHOBBHHe: 2

v - Ta rpyna aHT1-11-1H�ei<:UJ.103H1-1 nn 06oco6eea n03Hl(H.R NQ: 133 2

II.2.2) .l{oo'l,JIHHTeJJHH CPV KOAOBe 2

Ocxosea CPV KOJJ.: 1 33 690000 .[{OD'bJlHHTenee CPV xon: 1 2

YHn r:6d020ca-b I b9-4a0d-b987-<16b4S8968c2S 24

llaJ)'n,,11 06JlBJlEH)1£ 3A 81,JJlOJKEHA OOP'b'IKA (aepa<a 1)

Il.2.3) MJiCTO H8 H3D'bJIHeHHe OCROBBO MJICTO ea asrrsnaeaae: C50J1Hl1YHa anTe1<:a KO.II. NUI'S:1 BG341 ll.2.4) Omrcarrae ea o6�ecreeuaTa nop-snxa: (ecrecrao H KOJJH'leCTBO Ha CTpOHTeJJRH patiora, .noCTaBKH HJIH ycnyra HJJR yxaasane Ha D0Tpe6BOCTH 11 113HCKB3HH.11) 1334 Do.x:ycycline lOOmgtabl II.2.5) KpHTepHH 38 B'b3Jlar&He 1 2 O Kp11Tep11n 3a xasecrao - l1Me: / Texcecr: 1 2 2° O Kp11Tep11i,i, cespaan c pa3xOAH - 11.Me: / Tescecr: 1 2° � Ileaa - Te)KeCT: 21

Il.2.11) .HHct,OpM8J.{HJI OTBOCHO omrasrre OaQHR ,lla O He� Onacaaae Ha ODQHHTe:

Il.2.13) Hnct,opMa� oruocno cpeaeraa OT EeponeiicKHR C'l>J03 06meCTBeHaTa nops-uca e B'hB apsaxa c npoeier 11/HJJH nporpaera, q>HHaHc11paH/a C'bC ,lla O He� cpencrsa OT Eeponeacxas C'bl03 H.neHTHq>HK3QM Ha npoexra:

ll.2.4) ,llOO'bJIHHTCJJ.11.3 HHct,opM8J.{HJI!

PA3,[(FJI IV: IIPOl.(E,[(YPA IV.1) Onncaane IV.1.1) BHA npouenypa �OrKpHTa npouenypa

0YcKopeRa npouenypa 060CH08Ka:

OOrpaH11\feHa npouenypa 0YcKopena rrpouenypa

060CHOBKa: 00bcre3aTeJJHa npouenypa c norosapaue

0YcKopeHa npouenypa 060CHOBKa:

00bcre3aTe.neH zmanor OilapTHbOpCTBO 3a HHOB3UHH 0Bb3.11araHe ea nops-rsa 6e3 npeASapHTeJJHO ny6JJHJCYBaHe Ha 06.11R11eHHe 33 nopsxxa B Oq>HUHaJJeH

BeCTHHK Ha EsponeHCKHJI C'bl03 B CJJY'f3HTe, H36poeR-u no-nony (MOJJ.11, DOD'bJIHeTe DJ)HJJO>KeHHe fl) 0Ily6JJH4HO C'bCTe3aHHe nflp.RKO ,UOfOBapRHe (MOJLR, DOll'bJIHeTe l'IDHJJO>KeHHe f5) IV.1.3) Hnc}>opM8J.{HJI OTHOCHO p8MXOBO cnopaayssenne HJlH AffHaMH'IH8 CHCTeMa 38 DOKYJIKH 0Ta311 otiutecraeaa nopuxxa o6XBaJ.Ua CKJJIO\fB8HeTO Ha paMKOBO cnopaayaeaae 11YcraHoset1a e AHHaMH'IHa cHCTeMa aa noJ<YOKH IV.1.6) Huct,opM8l(HJI OTHOCHO eJJeK'IJ)OHHHJI Tbpr nl13DOJJ383H e e.neKTOOHeH rsnr IV.1.8) Huc}>opMal(HJI ornocao Cnopa3}'MeHHeTO 38 A'J>P:iKaBHH nop'h'IKH (GPA)

,lla O He� Ofiurecrseaara nopssxa nonaaa e o6XBaTa ea Coopa3JMeH11eTo aa m,p>KaBHH DOp-b\fKll (GPA) IV.2) AAMlfHHCrD8THBH8 HHc}>OpM&nHJI

IV.2.1) flpeAHIDH8 nyWIHK8J.{HJI OTHOCHO T83H npou.eAYl)a 2 Hossep 1-1a 06.11B11em1eTo BOB Ha EC: 2018/S 102-232623 Hoxep Ha 06.11BJJeHHeTO a POil:848940 (Ea1w om cneimume: 06R8/leHUe 3Q npeoeapumenna UH(POpMOl(llR, U3n01136UHO KQmO nOKQHQ 30 y1.1acmue e C'bCmeaame.ntta npo14ei}ypa; 06R8/leHUe ae nopt,1.1Ka; 06R8/leHUe 3a ao6poa011tta npo3pa1.1ttocm ex ante)

YHO c6d020u·blb9-4a0d-b987-d6b4S8968c2S 2S

06JIBJIEHHE 3A 81,JJJOJICEHA 001'1,'IKA (ocpouo 1)

IV.2.8) Hn<t>opMau,HJI OTHOCHO npeKp8TJIB&He Ha AJIH&MH'IHa CHCTeMa 38 DOKyDKH 006RBJieHHeTO ofixaauia rrpexparaaaaero Ha .l{HHllMR'IHaTa CHCTeMa 311 DOK}'DKH, ny6JIHK)'BaHa c

ropenocosenoro ofiaaneaae aa DOP'b'IKa

IV.2.9) HH<l>opM�HJI OTBOCHO npexparaaaae Ha C'bCTe38TeJIH8 npouenypa, 06J1Bena srpea 06.RBJieHHe 38 npezraapsrrezraa HH<l>OPMBIOUI 0B'b3Jlarauu,urr opraa tUIMa aa B'b3Jlara nosese DOp-b'IIOI B'b3 ocaoaa ua ropenocosenoro 06RBJiem1e aa

npezrsaparenaa HHffiOPMllUWI

PA3.ZJ:EJI V: B1>3JIAI'AHE HAilQP'l,qKATA t Ilopssxa N2 (Ilorosop N2): 06oco6eua no3HUWI N2: 2 5. 1, 5. 2, 5. 3 Haasseaoaaaaee I - Ba rpyna MeCTHM aHeCTeTMUM 8'b3JlO:>KeHa e DOp-b'IKa/o6oco6eHa II03Hl.lHJI .l(a D Hel8)

V.t) RH O MaIOUI OTHOCHO HCB'l>3JI8r8He

IlOP'b'IKaTa/o6oco6eua no3HUWI Hee B'b3JIO)l(eHa 18)He ca norryxeaa o<flepTH HJl11 3aRBJieHWI 311 ysaerae RJHI BCl1'1KH ca 6HJJH OTXB1>pnem1

.u H n H'HIRH (n ex arssaae ua II OU ara)

Oparaaanno o6RBJJeHHe, asnpareao spes 1

OeNotices OTED eSender 0.Up�o�����- IloTpe6HTe.TJCKO BJIH3ane e TED eSender: 1 _

Cnpasxa aa 06RBJ1eHHJ1:00DD-OOOOOO 7 (rozrana H HOMep Ha .l{OK}'MeHTa) ,ll,aTa aa H3fl amase Hao urHHaJIHOTO ofiaanenae: 1 M MM rrrr

V )B ,2 'b3.llaraue ua DOP'b'lKaTa

V.2.1) .l(aTa ea CKJIJO'IBaHe ea AOroeopa M/MM/rrrr

V.2.2) HH<l>opMBWiJI OTHOCBO o<t>eJ>TH 6poH Ha nonyseasre orpepra: 6poii aa orpeprare, OOCT'bDHJIH OT MCil: (MCil - KaKTo e onpeneneao a Ilpenopsxa 2003/361/EO Ha Kosracaara) 6poii aa o<flepYHTe, noersnana OT oq>epeHTH OT zrpyra .lfl>P)l(aBH - 'IJleHIOI Ha EC: 6pou Ha otpepnrre, IIOCTl,DHJIH OT oq>epeHTH OT .Lt1JP)l(aBH, KOHTO He ca 'IJleHKH Ha EC: 6poii Ha odieerare. nonvxeaa no e.TJeKTDOHeH 01,T:

IlOO'b'IKaTa e B'b3JIO)l(eHa Ha rovna OT HKOHOMR'leCKH OIIeoaTOOH .l(a D HeD

V.2.3) HaHMeHOB8HHe H azmec ea H30'b.llHHTe.JIJI 1

V.2.4) Hn<l>opM�HJI OTHOCHO CTOHROCTTB HB DOp'b'1KaTa/o6oco6eHaTa D03H� (6ea AB ce BKJIJO'IBB .l(.l(C) Il1,pa0Ha'lanua ofiuia nporaoaua CTOHHOCT ea nops-ucara/otiocotieaara no3�H.R: 2 Ofima CTOHHOCT Ha DOp-b'IKaTa/o6oco6eHaTa 003HU,HJI: HJJH Hai-1-HHCKa otpepra: / Hai-i-BHCOKa otpepra: KOHTO ca 83eTH npensar; Banyra: (so J>OMKOBU cnopa3yMeH.llR - 06U4a MOKCUMWIHa cmoiiuocm 3a maau o6oco6eHa n03t1t.4UR) (ea OUHCVofU�Hu cucmasru ac no,cymcu - cmoiittocm Ha nopeocama/ume 3a mcsu napmuoa, KORmo/Koumo He e/ca BK/11()'1.eHa/u a npeinnuuu o6R611eHUR se B'b3JlazaHe Ha nOp'b'IKU) (sa nop'b'IKU, 6a3upaHu Ha pcv,tKOBU cnopa3yMettUR; cxo moaa ce U3UCKBa - cmoiitt.ocm Ha nopuuxama/ume sc meau napmuoa, KORmo/Koumo Hee/ca BK/11()'1.eHa/u a npeauumu o6R611eHUR se 6'b3.IIQZQHe Ha nOP'b'IKU)

V.2.5) Hn4>opMBll;JUI OTHOCHO B'b3.118r8HeTO RB DOA}l311'bJIHHTe.TI/H D 11Ma B'b3MO)K}fOCT IIOp-b'IKaTa na 61>,ne 81>3JJO:>KeHa Ha no.i:tH3D'hJlHHTe.TJ/H Oroaaocr HJUl AJ1J1 OT nopuxxa'ra, KOHTO e B'b3MO:>Kfl0 na 61>.naT B'b3JlO)KeflH Ha DOAH3II'bJJHHTeJIH 4 CTonHocr, 6e3 na ce BKJ110<1sa .U.UC: Banyra: J:lRJJ: % KpaTKO onacaaae Ha aena OT DOp-b'IKaTa, KOHTO me 61>.ne B'b3JIO:>KeH Ha DO)Ul3ll'bJJHHTe.TJH:

YHn c6d020oa·b I b9-4a0d-b987-d6b4S8968c2S 26

ll.tJ71HJ>I. 06ABJIEHl1.E 3A 81,JJJOJICEHA nOP'b'lKA (aepCM.11 7)

PA3.[(E.71 V: B1>3JIATAHE HA nonqKATA 1

Ilopssxa N!! Uloroeop N!!): 06oco6eHa aoaHUH..R N!!: 2 8. 3 Haseaeuoaaane: II - pa rpyna nep��epH� Ml10penaKCaHT� (HepBHO-MYCKynH� OnoKep�) 81>3JJO)KeHa e aop,,l!Ka/ ofiocotieaa TI03HJ.IH..R

V.t) lfH O Mat(HJI OTHOCBO HCB'1>3JJ8.r8He

.naD He�

Ilop,,qKaTa/o6oco6eHa no3HUW1 Ree B'b3JlO)KeBa �He ca ncnyseaa orpepra HJJH 3aJIBJieeH..R aa ysaerae HJJH ecK'!KH ca 6HJm OTX1rbp11eHH

Jl H n H'fHBH (n eK araaaae ua n oue ara)

OpHraHaJJHO 06.11BJieHHe, H3npaTCHO spea 7 DeNotices

OTED eSender 0Jlpyro������ IlOTpe6HTeJJCKo B11H3aHe B TED eSender: 1 _

Cnpasxa aa 06.11B11eHH..R:0000-000000 7 (roaaaa H ROMep Ha /lOK)'M6HTa) l{aTa Ra H30 amane Ha O IUHHaJJHOTO 06.11BJ1eHHC: 7 IJJJ. MM rrrr V )B .2 'b3JJ&.r8He Ha DOP'h'IK8TB

V.2.1) .l{BTB ua CKJJJO'IBaHe Ha zroroaopa JJJJ.! MM I rrrr

V.2.2) BH(}>OpM8l(HJI OTHOCHO o(}>epTH

6poe Ha nonyseawre oq>epTH: 6poi-i Ha oq>epTHTe, aoCT1>nHJJH OT MCil: (MCil - KaKTO e onpeneneao e Ilpenopsxa 2003/361/EO Ha KOMHCH..RTa) 6poi:i ua oq>epnrre, noCT1>nHJJH OT orpepeura OT npyra .zn,p)l{aBH - 'UleHKH ea EC: 6poH Ha o<j)epTHTe, noCTbnRJJH OT oq>epeHTH OT .Al>P)l{aBH, KOHTO ee ca 'IJleHKH Ha EC: 600H Ha odieprare, nonvsea» no eneKTOOHeR O'bT:

Ilopsxxara e B'b3JIO)l{CHa ea rpyna OT HKOHOMJ,lqeCKH oneparopa .naD HeD

V.2.3) HaHMeHOB8HHe H 8llDCC Ha H3D'h.llHHTeJIJI 1

V.2.4) BH(}>OpMat(HJI OTBOCHO CTOHHOCTTB BB 00p'h'I.KBTa/o6oco6eHaTB D03HJJ)UI (6e3 AB ce BK.IJJO'IBa tu(C) Il1,peoHa'!anHa ofiura nporuoaaa croauocr Ha uops-ncara/otiocotieeara no3HUW1: 2

061.1.(a croiinoer ua nops-ncara/otiocodeeara noaxuas: HJIH Hae-HHCKa ocpepTa: / Haa-ancoxa odiepra: KOHTO ca B3eTH npe.11.BH.A Banyra: (3a paMKoau cnopa3yMeHUR - o6iqa MQKCUMQ/IHQ cmoiiuocm 3a mQ3U o6oco6eHQ no3Ulfu.R) (sa 3wtOMU'lHU cucmeau 3Q noKl}nKU - cmoi1.Hocm HQ nOJYb'lKQmQ/ume 3a mcsu napmuba, xonmo/xoumo Hee/ca 6K.IIIO'leHQ/U 8 npeOOWHU o6R6JleHUR 3Q 6'l>3/IQZQHe HQ nO]Yb'lKU) (sa nO]Yb'lKU, 00.3UpaHU HQ paMK08U cnopa3yMeHUR; QKO m06Q ce U3UCK6Q - ctnoiinocm HQ nopmxama/ume 3a maau napmuba, xonmo/xoumo He e/ca BK.IIIO'leHQ/u a npeouumu o6R6JleHUR 3Q 61>3/IQZQHe HQ notrsuxu)

V.2.5) Bu(}>OpMat(HJI OTHOCHO B'b3JJ8.r8HeTO BB DOA}l3lrb.llllHTeJI/H D HMa B'b3M0)1{80CT DOJ)1,'fKaTa .11.a 61.lle B'b3JIO)l{eHa aa no.AH3ffb.lJ..BHTCJJ/H CTOHHOCT HJIH A.RJ1 OT 001)1,'fKaTa, KOHTO e B'b3MO>KHO .11.a 61>.AaT 81,3.IJO)l{eHH Ha 00,llH30'b.llHHTCJlH 4

CTOHHOCT, 6ea .11.a ce axmosaa .l]J.lC: Banyra: ,UJI.Jl: % KpaTKO OOHcaB.He Ha nena OT nopssxara, KORTO 1.1.(C 61..11.e B'b3JIO)KeH Ha OO/lH3D'b.llHHTeJIH:

PA3�EJI V: B1>3JIATAHE HA nonqKATA l Ilopsxxa N!! Ulorooop N!!): Otiocofieaa no3HUWI N!!: 2 15.5 HBHMeHOBBBBe: I - ea rpyna nn, Ae�cTeam� s�pxy �HC 8'h3.IJO)f(eHa e noJYb1.1Ka/06oco6eHa oo3HUHJI V.1) HH(}>opMB.QHJI OTHOCHO HeB'b3JJ&.raHe

.l{a D He181

YtUl c6d020..·b lb9-4e0d-b987-<16b4SB968c2S 27

Jlapnulll 06JIBJI.EHl1E JA BWIOJICEHA I JQP1,'ll(A (IICJ)<KA 7)

Jlops-ucara/odocoeieaa no3HUHJI Hee B'h3JIO)Keea 181He ca TIOJJ}"-leHH orpepra HJUt 3aJIBJJeewi 33 }"-13CTHe HJJH BC�KH ca 6HJJH OTXB'bpJJeHH

.ll H n lf'IHHH (n ex arasaae ea n ou ara) OpHrHHaJIHO 06'1BJJeHHe, H3DpaTeHo spea 7 OeNotices 0TED eSender

0.llpyro ------ Ilorpefia'rencxo BJJH3atte a TED eSender: 1 _

Cnpasxa 33 06,rn11eeHJ1:0000-000000 7 (rOAHHa H aossep ea AOK)'MeHTa) .llaTa ea aan amaae ea o HntHaJJllOTO 0611BJJeeue: 1 AA MM rrrr V )B ,2 'b3Jlaraue ua nop'.bqJ(aTa

V.2.1) .l).aTa na cKJIJO'IBaue na p;oroeopa M/MM/rrrr

V.2,2) liHct,opM�H.H OTHOCHO oct,epnr 6poii ea nonyxeaare oq>eprn: 6poii ea ocpepTIITe, noCT'baHJJH OT MCn: (MCn - KaKTo e onpeaeneno a Ilpenopsxa 2003/361/EO ea KoMecHJ1Ta) 6poii Ha oq>epnlTe, OOCT'bOHJJH OT 04>epeHTH OT APyTH ,A'bp)KaBH - 'l/leHKH Ha EC: 6poii Ha orpeprare, TIOCT'bOHJJH OT otpepeura OT A'hP)K3BH, KOHTO He ca '-IJJeHKH Ha EC: 6000 ea odieprare, OOJJV'-leeH no eJJeKTOOHeH U'bT:

Ilorrsxxara e B'b3JIO)KeHa ea rovna OT HKOHOMH"leCKH onenarona .ll.aO HeO

V.2.3) HaHMCHOBaHHe H azmec Ha H31l'hJIHHTCJJJI 1

V.2.4) HHct,opM�H.H OTHOCHO CTOHHOCTTa Ha DOp'.bql(8Ta/o6oco6eHaTa D03HIU{JI (6ea p;a ce BKJl1011B8 MC) nopaoeaYanea o6ma nporuoaaa eroauocr ea nopo"1KaTa/o6oco6enaTa no3HUHJI: 2

06ma CTOHHOCT ea nopssxara/oeocotieuara 003HUHJI: HJIH Baii-HHCKa odiepra: / Haii-BHCOKa orpepra: KOHTO ca 83eTH apeABHA Banyra: (sa pa.MKOBU cnopa3yMeHUR - o6r.qa MaKCUMaJIHa cmoi1Hocm 3a mcau o6oco6eHa nosuuua) (sa auHOMU"->tU cucmessu sc no,cynKU - cmoi1Hocm Ha nOJJl,"-Kama/ume 3a meau napmuba, xosuno/xoumo He e/ca BK/110"-eHa/u a npeouuinu 06RB11eHUR 3Q B'b3/I.QZQHe Ha nO/J'b"-KU) (ea nop'b'IKU, 6a3upQHu HQ paMKOBu cnopa3yMeHUR; QKO moaa ce U3UCKBQ - cmouxocm HQ nopv-oaima/ume 3a meau napmuba, xosmo/xoumo He e/ca BK/lKJ'-leHa/u a npeinnuxu o6RBJ1ettUR 3a B'b3/laZaHe HQ nOJ}'b'IKU)

V.2.5) HHct,OpM�H.H OTHOCHO B'b3Jl8r8HCTO Ha DOp;H3D'bJIHHTCJJ/H D M:Ma B'b3MO)KHOCT nopsaxara .11a 6o.Ae B'b3JJO)Ketta ea DOAH3D'bJJHHTeJJ/H CTOKHOCT HJIH ,AJ1JJ OT DOp'b'IKaTa, KOHTO e B'b3MO)KH0 A3 6o.11aT Bo3JJO)KeHH ea DOAH3D'bJJHliTeJJH 4

CTOHHOCT, 6e3 .11a ce BKJII0\.188 .u.nc: Banyra: .llJ1JJ: % KpaTKO OOHcaHHe Ha AeJJa OT TIOp'b'IKaTa, KOHTO uie 6o,Ae B'b3JIO)Kee ea OOAH30'bJJHHTeJJH:

PA3.l(FJIV: B'b3.71ArAHEHAilOP'bqKATA 1

Jlopsxsa NQ (.lloroeop NQ): 06oco6eea ao3HQHJI NQ: 2 16.3 ff8HMCHOB8HHC: II - pa rpyna nn, �eHcTaaw� s�pxy UHC Bo3JIO)Keea e nopo"iKa/o6oco6eea ao3HUHJI

V.1) IIH O M8.IOIJI OTHOCHO HCB'.b3.11Br8He

.ll.aO He181

Ilopo'-1KaTa/o6oco6eea aoaHQHJI ae e B'b3JIO)Keea 181He ca uonyseua orpepra Hllli 38JIBJJeHHJI aa }"-13CTHe HJJH BCli-.iKH ca 6HJJH OTXB'bpJieHH

)l rH n H'IHllH (a ex arxsaue ea n ou ara)

OpHrHHaJJHO 0611BJJeHHe, H3DpaTeHO xpea 7 OeNotices 0TED eSender [J.llpyro _ IlOTpe6HTeJJCKo BJJH3aHe B TED eSender: 1 _

Cn 3BKa aa o6RBJJeHliH: 7 (ronaua H eoMe enra)

YHJl c6d020ca·b 1 b9-4.od·b987..S�S896Sc2S 28

06118.IIEHHE 3A 81,3JJOJi.'EHA OOP'l>'IJ(I. (acpc;MJ1 7)

I .llaTa Ha HanpamaHe aa opHrHHMHOTO 06.11BJieHHe: 1 JlJl/MM/rrrr

V )B ,2 '1,3Jlara.ne Ha DOP'b'IKaTa

V.2.1) .ll:aTa ua CK.IJ10qeaHe Ha noroaopa JlJl/MM/rrrr

V.2.2) Hiu}>OpM8}4HJI OTHOCHO o(}>epTH 6poH Ha DOJIY'leHHTe orpepra: 6poii Ha oct>epnrre, noCTbDWIH OT MCn: (MCil - KaKTO e onpeaeneao e Ilpenopsxa 2003/361/EO Ha KOMHCHJ!Ta) 6poH Ha otpeprirre, OOCTbIDUIH OT oct>epeeTH OT zrpyra ,l.l'bp>Ka:BH - 'IJleHKH Ha EC: Bpoii Ha o<t>epTHTe, DOCTbDHJIH OT 04>epeHTH OT ,l.l'bp>KaBH, KOHTO He ca 'UleHKH Ha EC: 6poii Ha odieprare, nonysean no enescrpoaea O'bT:

IlO})'.b'IKaTa e B'b3JIO)Ketta Ha rpyna OT liKOHOMH'leCKB oneparopa .ll:aO HeO

V.2.3) BBHMeHoeaHHe H azmec Ha H3D'b.llHHTeJJJI 1

V.2.4) IIH(}>opM8}4HJI OTHOCHO CTOHHOCTT8 Ha nOp'b'IK8T8/o6oco6eHaTa 003� (6ea AB ce eKJDOqea MC) Il'spaoaaaanna ofima uporaoaaa croauocr ea nops-ncara/oeocooeaara D03HUH.R: 2

06J.Ua CTOKHOCT Ra nopvsxara/otiocotieaara D03HUHJI: runt HaH-HHcKa odiepra: / HaH-BHCOKa orpepra: KOHTO ca B3eTl1 npeaaan Barryra: (sa pOMKOBU cnopa3y.MeHWl - OOU{a MOKCUMOJIHQ cmoiiuocm 3a rncau o6oco6eHa no3u14wt) (sa ouHOMlNHU cucmaau 3a no,cymru - cmoiinocm Ha nOp-t,'IKama/ume 3a mcsu napmuoa, xosmo/xoumo ne e/ca 6K1110'le1w/u a npeinnuuu o6R6/lel-CWl 3a 6'b3/lazaue Ha nopvocu) (ea nop'b'IKU, 6a3upauu Ha pOMKoau cnopasipeenu«; a1<0 moaa ce usucxee - cmouuocm Ha nop-t,'IKama/ume 3a mcsu napmuoa, xosmo/xoumo Hee/ca BKAIOtteHa/u a npeouumu o6R611eHWl 3a 8o3.IIQZOHe HQ nOJn,'IKU)

V.2.5) 11.n(}>opM� OTHOCHO B'l,3JIBr8HeTO Ha DOAH3Il'bJJHHTeJI/H D 11Ma B'b3MO)KROCT nopsasara na 6'b.ne B'b3JIO>KeHa ua no.l.{H3D'bJ1HHTe.ll/H CTOHHOCT HJIH .llJl}I OT nopssncara, KOHTO e B'b3MO>KHO aa 6'b.naT B'b3JIO)KeHH Ha OO,l.lH3D'bJJHHTeJJH 4 CToi%HoCT, 6ea na ce sxmoaaa .ll.llC: Banyra: ,ll.llJl: % KpaTKO ODHcaHHe Ha .nena OT nopi.sxara, KOHTO uie 6'b.ne B'b3JIO)KeH Ra OOJ.lH3D'bJJHHTeJnt:

PA3.UEJI V: B'L3JI.AI'AHE HA IIOP'bqKATA 1

Ilops-rxa NQ (J{oroeop NQ): 06oco6eea D03H1{JUI NQ: 2 27.3 - 27.6 HaHMeHOBaHHe: I - ea rpyna nn, �e�cTaa�� a�pxy CCC B1>3llo>Keea e no})'.bqKa/o6oco6eHa D03HUHJI

V.1) HH o M� OTHOCHO Hee'b3JlaraHe

.ll:a D He181

Ilo})'.bqKaTa/o6oco6eHa no3HUHJt Hee B'b3JJo>KeHa 181He ca nonysena oct>epTH HJIH 3a.RBJleHHJI aa ysacrae HJIH BCH'-IKH ca 6HJJH OTXB'bpJleHH

.ll rn a H'IHliH (n eic araaase ea n ou ara)

OpHrHHMHO ofornneHHe, H3npaTeHO spea 7

DeNotices OTED eSender 0.llpyro�����- IloTPe6HTeJ1CKO MH3aHe B TED eSender: 1 _

Cnpauxa aa 06siBJ1euHJ1:0000-[JO[JOOO 7 (ronnaa R HOMep Ra .llOtcyMeHTa) .llaTa Ha H30 auiaae Ha O HTHHaJJBOTO 06.11BJ1eHHe: 7 JlJl MM rrrr

V.2) B'sanaraae Ha nop'bqKaTa

V.2.1) .ll:aTa Ha CKJJJO'IBaHe HaJJ;oroeopa JlJl/MM/rrrr

V.2,2) Hu(}>opM8}4HJI OTHOCHO o(}>epTH 6poi% Ha nonyqeaHTe 04>ep-r11: -------- 6poi1 Ha oq>epnrre, oOCTbDWJH OT MCil: -------- (MCil - KaKTo e onpeneneao e Ilpenorrsxa 200::1/361/EO Ha KoMHCli.llTa)

YHJ1. o6d020c:a-blb9-4a0d-b987·d6b4S8968c25 29

06JlBJIEHHE JA 81.lllOlKl!HA l lQPl,'IXA ("<!'C>IJI 7)

Epoe Ha o<t>eJ>THTe, nOCTbDHJlH OT orpepeara OT npyra .Uop)KaBH - 'IJleHKl1 Ha EC: 6poe Ha o<t>eJ>THTe, nocrsnana OT o<f>epeHTH OT zrspseaaa, KOHTO He ca 'IJleHKH Ha EC: 6pon ea o<t>epnlTe, oOJJY'leHH no enexrpoaea 01>T:

Ilorrssxara e B'b3JIO)KeHa Ha rpvna OT HlCOHOMH'leCKH onenarona .naD HeD

V.2.3) HaHMeeoe&HHe e azmec ea H3IrbiJHHTeJIJI 1

v.2.4) IIHcl>opM8JJ){JI OTeOCRO CTOHHOCTl'a H8 D0p'b'IJ(aTa/o6oco6eHaTa 003� (6e3 .11.a ce BKJIJO'llJ8 MC) Il'spaoaasanna ofiura nporaoaaa CTOHHOCT Ha DOp'b'IKaTa/o6oco6eHaTa nosnuaa: 2

06m.a CTOHHOCT Ha DQp'bq]CaTa/o6oco6eHaTa D03HL{HJI: HJJH Haii-HHCKa orpepra: / Haji-aacoxa orpepra: KOHTO ca aaera ope.uaH.u Banyra: (3o paMKoau cnopa3yMe>tWI - o6t14a MaKCUMcut>ta cmou>tocm 30 masu o6oco6e>ta noauuus) (sa Ou>tOMU"l>tU cucme.Mu 3o no1qJnKU - cmoiJ.>tocm >to nopvoaima/ume 30 mcsu napmuba, xosuno/xoumo ne e/ca BKAIO"leHa/u a npeinnuuu 06st6.lleH.W1 30 a'b3/laeaH.e Ha nop'b"IKU) (30 nOpb"IKU, 003UpOHU H.O pOMKOBU cnopo3yMeH.WI; OKO moao ce U3UCK60 - cmoiJ.Hocm HQ nopv-xama/ume 3a mcsu napmuba, xonmo/xoumo Hee/ca a1U1.10"leHa/u a npeouiunu o6st6.lleHW1 30 6'b3/lQZOHe HQ notreocu)

V.2.5) llHcl>OpM8JJ){JI oruocao B'b3Jl8r8He'l'O ea DOA)f3D'bJIHHTeJ1/H D l1Ma B'b3MO>KBOCT nopssxara .ua fu.ne B'b3JTO)KeHa Ha ao,nu3n1,JJHHTe.n/H CTOHHOCT HJTH )lM OT 00!)1,'IKaTa, KOHTO e B'b3M0)KH0 .ua fu,naT B'b3JTO)KeAH Ha no)lH3D1,.llHHTeJIH 4

CToi%HoCT, 6ea na ce BKJJJOqaa .ll.llC: Banyra: .llJUI: % KpaTKO onacaaae Ha nena OT nopssxara, KOHTO me fu.ue B'b3JTO)KeH Ha 00)lH3D1,JJHHTeJJH:

P A3.[(F.JI V: B'b3JIAI' AHE HA OQP'bqKATA 1

Iloptonca NQ Uloroaop NQ): 06oco6eHa no3HUHJI NQ: 2 28.3, 28.5 - 28.7 HaHMeeoeaHHe: II - pa rpyna nn, �e�CTBa�� B�pxy CCC 8'b3JIO)KeHa e nopsvxa/otiocotieua no3HUHJI

V.1) IIH o MaJ.UUI OTHOCHO eee'b3Jlaraee

Ilop'bqJCaTa/o6oco6eHa no3HUH-R Hee B'b3JIO)KeHa 181He ca 00.IIY'leHH odiepra HllH 38RBJJeHH.H 38 ysaerae HllH BCffqKH ca 6HJTR orxsupneaa

)l H a HqHHH. (n ex aT.RBaHe ea a ou ara) OpH.rHHaJIHO 0611B.11eHHe, H3opaTeHO spea 7

DeNotices OTED eSeoder 0.llpyro������- Ilcrpeforrencso BJJH3aHe s TED eSender: 7 _

Crrpasxa 33 06.RBJleHH.11:0000-000000 7 (ronaaa H HOMep Ha .UOKYMeHTa) .llaTa Ha H30 aniaae Ha O HrHHaJIHOTO 0611BJ1eH11e: 7 IJJJ. MM rrrr

V.2.1) .l{aTa ea CKJJJO'llJaee ea .11,oroeopa 1JJJ. MM rrrr

.l{a D Hei81

v.2.2) HHcl>opM8J.{HJ'I OTHOCRO ocl>eIJTH 6poii Ha nonyqeeHTe 04>epTH: -------- 6poe Ha odieprare, nocrsnana OT MCil: _ (MCIT - KaKTo e onpeaeneuo s Ilpenopsxa 2003/361/EO Ha KoMJ1C.H.11Ta) 6poii Ha oq>epniTe, noCTbDHJTH OT orpepeura OT npyra .A'hP)K3BH - 'IJleAKH Ha EC: _ 6poH Ha o<t>epTHTe, llOCTbDKIIH OT orpepeara OT ,1(1,p)KaBH, KOHTO He ca qneHKH Ha EC:-------- 6 OH Ha O e THTe DOJJ eHH DO enexr OHeR n1>T:

ec ea H3Irh.71HHTCJIJI 1

3TO H .UaD HeD

V.2.4) Hecl>opMaJ.OUI OTHOCRO CTOHHocrra Ha noJ)'bqKaTa/o6oco6eHaTa noa�HJI (6ea .11,a ce BKJIJO'I.Ba MC) n,, aoaaxanaa o6ma a OrH03Ha CTOHHOCT Ha 00 xxara ofiocofieuara 003HUHH: 2

Ytlfl e6d020oo,blb9-410d·b917-d6b4SB968c2S 30

06JIBJIEHHE JA 81.lilOlKEHA nOP'l.'UCA (oq,0t• 7)

Ofinia CTOHHOCT Ha nopscxara/otiocotieaara II03HUIUI: MH HaH-HBCKa orpepra: / HaH-BHCOKa orpepra: KOHTO ca B3eTH apeABH.U Banyra: (3Q pC1M1<oau cnop03yMe1tUR - 0011.jQ MOKCUMaJIHa cmoiinocm 3Q mQ3U o6oco6e1tQ no3Ul{UR) (3Q ouHa.MU�Hu cucmeMu 3Q no,qJnKU - cmoiinocm HQ nopuuxama/ume 30 maau napmuoa, xonmo/xoumo He e/ca a1U110�eHa/u a npeinuunu o6R6/leHUR 3Q a'b311Qzane Ha nopvocu) (3Q nop7,�KU, 6a3upaHu HQ pw.11<oau cnopasipsenu»; QKO mosc ce U3UCK6Q - cmoiiuocm HQ nopvuxama/ume 3Q mQ3U napmuoa, xasmo/xoumo He e/ca a1<1uo�eHQ/u a npeinuunu o6R6/leHUR 3Q 6'b3/IQZQHe HQ nopvocu)

V.2.5) lhut,opMaJOIJI OTHOCBO B'h3.llaraue-ro Ra DOAH31I"hJJHHTeJJ/H D liMa B'h3Mo>Kttocr nopsxsara ,1:1a 6'h,1:1e B'b3JlO>KeHa Ha no,1:1Hano11HHTe.11/H CroHHOCT HJUI .LVIJ] OT IIOP,,"IKaTa, KOHTO e B'b3MO>KRO ,1:1a 6'bAaT B'b3JlO>KeHH Ha IIO,UH3Il'hllHHTeJ1H 4

Cro11Hocr, 6ea .ua ce BKJJIO<flla MC: Banyra: ,UJ!Jl: % KpaTKO ODHcaHHe Ha ,UeJla OT nopsaxara, KOHTO me 6'b.ue B'b3JlO>KeH Ha IIO.QH3Il'bJIHHTeJ1H:

P A3,ZlE.ll V: B'b3.71Ar AHE HA IlOP'bqJCATA t Ilopuvxa NQ (.LJ.oroaop NQ): 06oco6eea no3HUHR NQ: 2 32.6 HaeMeeoe8JIHe: VI - Ta rpyna nn, Ae�cTsamH Bbpxy CCC B'b3JlO>KeHa e aop,,qKa/o6oco6eHa noaauas V.1) HK o MaJOIJI ornoca« eee'h3.llaraue

.Z:.a D He181

Ilop:b<1KaTa/06oco6eHa nosauaa Hee B'b3JlO>KeHa 181He ca DOJI�eBll oq>epnt lUIH 3aRllJleHHR aa yxacrae HJIH BCH"IKH ca 6MH OTXB'bpneHH

.n H II �HHH (n ex aTHBaHe ea a ou ara) OplffHHaJIHO otiasnenae, asnpareno xpea 7

DeNotices OTED eSender 0.llpyro ------ Ilorpetiarencso anaaaue s TED eSender: 7 _ Cnpaaxa sa 06HBJ1eHID1 :0000-000000 7 (rO,LIHHa H HOMep Ha AOK)'MeHTa) ,UaTa Ha H3II ainaae Ha O lffHHaJIHOTO 06HBJJeHHe: 7 AA MM rrrr

v.2) B'h3.llar8He Ha DO 'h'IKaTa

V.2.1) .Z:.aTa ea CK1UO'IB8He ea ,11.oroeopa AA MM rrrr

aD HeO aTO H

V.2.2) HHct,opM� OTHOCBO oct,epTH Epoii Ha no�ett11Te orpepra: -------- Epoii Ha otpeprare, nOCTbDHJJH OT MCil: -------- (MCn - KaKTo e onpeaeneao a Ilpenopsxa 2003/361/EO Ha KOMHCHRTa) Bpoa Ha o<t>ePTHTe, noCT'bOHJJH OT oq>epeHTH OT APYfH ,n'bp>KaBH - \fJJeHKH Ha EC: -------­ Epou Ha odiepnrre, OOCTbDHJJl1 OT orpepeara OT .Lli>PJfCaBH, KORTO He ca \fJleHKH Ha EC:-------- 6 oi,i Hao e HTe, non

V.2.4) HHct,opM�KR ornocno croHHocrra rra nop'h'I.K8Ta/o6oco6eeaTa noaunKR (6ea ,11.a ce BKJJJO'IBa MC) Il'bpBOHa'laJJHa 0611,\a nporaoaua CTOHHOCT Ha nops-ucara/odocoeesara II03HUIUI: 2 Ofiura CTOHHOCT Ha IIOP,,"1KaTa/o6oco6eHaTa II03HUHJI: HJJH HaH-HHCKa odiepra: / Haa-aacoxa odiepra: KOHTO ca B3eTH npe.QBH.LI Banyra: (3Q pa.MK06u cnopQ3yMeHUR - OOUjQ MaKCUMaJIHQ cmouHocm 3Q mcsu o6oco6e1tQ no3Ul{UR) (3Q ouHa.Mu�Hu cucmaau 3Q no,qJnKU - cmoiinocm HQ nopwoaxma/ume 3Q mQ3U napmuba, xonmo/xoumo He e/ca 61U110'l.eHa/u a npeinnuuu o6R6/leHUR 3a B'b311Qzaue Ha nOpl>'lKU) (3Q nop7,�KU, 6a3upaHu HQ pa.MKOBu cnopQ3yMeHUR; QKO mosc ce U3UCKaa - cmouHocm HQ nopv-xama/ume se mcsu napmuba, xonmo/xoumo He e/ca BIUIIO�eHa/u a npeinuuuu o6R6/leHUR ac 61,3/IQZQHe HQ no 'I.KU)

YHTI: c6d020ca-b I b9-4a0d·b987 -d6b4S8968c25 31

llapTHJlJL 06J!BJ!EH}!E 3A 81,JJJO)l(EHA nQPl,'IKA (aepc"" 7)

V.2.5) Hecl>opM8J.(HJI OTHOCHO B'b3.118J'aHeTO Ha OOAfl31I'hJJHHTeJI/H D 11Ma B'b3MO)K}fOCT nopsxsara na fu.Ae Bo3JIO)Keea aa no.nH31J'h.TJHHTe.n/11 Croauocr H.1IH ,AJIJI OT IlOJYbqKaTa, KOHTO e B'b3MO)KH0 na fu.naT B'b3JIO)KeRH Ha DO,ZU,t3Jl'bJ1HHTeJIH 4 CroHHOCT, fiea ,Aa ce BKJIIO'{Ba .[{.[{C: Ba.nyra: .l{JUJ: % KpaT.KO OJJHcaHHe Ha aena OT nop's-neara, KOHTO me 6'b,Ae B'b3J10)KeR Ha 110,UH31l'bJ1HHTeJIH:

PA3.l(FJI V: B1,3JIAI'AHE HA IlOP1,qKATA 1

Ilopsxxa NQ (Zloroaop NQ): Ofiocofiena noaHQHJI NQ: 2

HaHMeHoeauue: 34.6, 34.7

B'h3JlO>KeHa e nop'bqKa/o6oco6eHa noamras

V.1) HH O M8J.(HJI OTHOCHO HeB'b3.1181'8He

Ilopasxara/otiocotieaa noa0QHJ1 Hee B'b3JIO)Keea l&!He ca norrysena oqiepra HJIH 3aJ!BJ1eHW! aa ysaerae IUJH BCH'{KH ca 61UJH OTXB'bplleHR Ll H n H'IHHH (n e ara) OpHTHHaJIHO 06'1BJ1eHHe, aanpareuo xpea 7 OeNotices OTED eSender DLlPYTO������ TI0Tpe6HTenc.1<0 anasaae a TED eSender: 1 _

Cnpanxa aa 06»BJ1eeHJ1:000[]-000000 1 (rozraaa H HOMep ea .uoK)'MeHTa) )J.aTa Ha H3D amaae Ha O HrHHaJIHOTO 06»BJ1eHHe: 7 AA MM rrrr

.[(a D Hel&I

V.2) B'b3Jlaraue Ha oOD'b'IXaTa

V.2.1) .[(aTa Ha CKJIIO'IB8He Ha ztoroaopa M/MM!rrrr

V.2.2) Hecl>opMa� OTHOCBO ocI>eJ>TH Bpoa ea DOJ1}"1ee1ne orpepra: Epoe ea oct>epTHTe, noCT'bnH.TIB or MCTI: (MCTI - KaKTo e onpeaeneao B Ilpenopsxa 2003/361/EO ea KOMHCHHTa) Epoe ea oct>ePTHTe, noCT'bDIUIH OT odiepenra OT zrpyra A'bp)KaBR - qJ]eHKH Ha EC: Bpoii ea oqieprare, DOCT'bllHJIH OT odiepeara OT .U'bp>KaBR, .KOHTO ae ca qJ]eBKH Ha EC: Epoii ea o<bePTHre, noJTV'leHH no enexrooaea 01,r:

Ilotrasxara e B'b3JlO)Keea ea rnvna or HKOHOMH"!ecKH oneuarona .[(a0 HeD V.2.�) HaHMeHOB8HHe H azmec Ha H3D'hJ1HHTeJIJI 1

V.2.4) HecI>opM8J.(HJI OTHOCHO CTOHHOCTTa Ba nop'b11K8Ta/o6oco6eHaTa 003� (6ea A8 ce BKJIIO'IBa .[(.[(C) Il'spaouaaanaa ofima nporuosaa eroaaocr ea nopssxara/ofiocofieaara noaauaa: 2 Ofima CTOHHOCT Ha nopsaxara/ofiocofieuara D03Hl{H.R: HJIH Haii-HHCKa oqiepra: / Haii-BRCOKa otpepra: KOHTO ca B3eTH npe,ABH,A Banyra: (3Q paMKoau cnopQ3yMeHWl - OOU{Q .MQKCUMQJIHQ cmoiinocm 3Q mesu o6oco6eHa nosu!.fUR) (3Q auHaMU'lHU cucme.Mu 3Q no,cyn,cu - cmoiinocm HQ nopusxama/ume 3Q meau napmuoa, xoxmo/xoumo He e/ca BKIIJO'l.eHa/u a npeouumu o6st8JleHUR 3a 6o3.flazaHe HQ nopu-ocu) (sa nopo'l.KU, 6a3upaHu Ha paMKoau cnopasipsenus«; cxo moaa ce uaucxsc - cmoiinocm Ha nopa'l.KamQ/ume 3a ma3u napmuoa, xonmo/xoumo Hee/ca a1<1110'l.eHa/u a npeouuiuu o6st8JleHWl sa 61>311QZQHe HQ nODo'l.KU)

V.2.5) HHcl>opMBJ.\JUI OTHOCHO B'b3.118r8HeTO Ha DOAfl31I'hJJHHTeJI/H D HMa B'b3MO>KHOCT OOJYb'IKaTa .ua 61,.ue B'b3JJO)KeHa Ha oo,AH31J'h.TJHHTe.n/H Croanocr HJIH ,UHJI OT IlOJYb'lKaTa, .KOHTO e Bo3MO>KHO ,Aa fu,AaT B'b3J10)KeHH Ha DO,AH3D'bJJHHTeJIH 4 CroiiHOCT, fies na ce BKJIIOqsa .l{L{C: Banyra: L{JUJ: % KpaT.KO ODHCaHHe Ha ziena OT OOp'b'IKaTa, KOHTO me fi'b,Ae B'b3JIO>KeH Ha DO,AB3ll'bJIHHTeJIH:

YHI I: e6d020ca-b lb9·4a0d·b987 ·d6b4S8968c2S 32

06.RBJlE.HliE 3A B'b3JIOJICEHA nOP'b'IKA (acpc•• 7)

PA3�EJIV: B'b3.7IAI'AHE HAilOP'b'lJKATA t Tiopo.:i1<a NQ (,l(oroBop N2): Ofiocotiena D03HUWI NQ: 2 36.9 - 36.11 ffaHMCHOBaHHC: I - pa rpyna ACE MHXMDMTOPM B'sanosceaa e aopo.:i1<a/06oco6eHa no3H�HJI

V.1) IIH O M� OTHOCHO HeB'h3.llaraHe .UaO He�

Ilops-neara/ofiocodeua D03HUWI Hee B'b3JlO)KeHa �He ca DOJl}"leHH ocpeprn HJIH 3aJIBJieHHJI aa )"{aCTHe HJIH BCfft.lKH ca 6rurn OTXB'bpJieJfH

.l( H n fft.lHHH (a e araaaae Ha n one ara)

OpHTHHaJIHO 06.RRJieHHe, H3apaTeHO t1pe3 7 OeNotices 0TED eSender 0.l(pyro _ TI0Tpe611Tenc1<0 BJIB3rute B TED eSender: 1 _

Cnpasxa aa 06.RR.11eHHJ1:[)[]00-0000[]0 7 (rozraaa H HOMep Ha AOK)'MeHTa) .l(aTa ea 1130 amane Hao HrHHaJIHOTO ofiaanenae: 1 M MM rrrr V )B .2 'h3.llaraHe Ha DOl>'b'IKaTa

V.2.1) .UaTa Ha cK.111oquaHe Ha zroroaopa M/MM/rrrr

V.2.2) 11H4>opM� OTHOCHO 04>epTH Bpoji Ha nozrysemrre 04>epTH: 6poii Ha orpeprare, DOCT'bllHJIH OT MCil: (MCll - Ka.KTO e onpezteneno B Ilpenopsxa 2003/361/EO Ha KOMHCH.RTa) Iipoi.\ Ha otpeprare, noCTbnHJIH OT otpepeura or APYTH .nopmaeH - LLJieliKH Ha EC: Epoii Ha 04>epTHTe, DOCTbDWlH OT o<t>epeHTH OT A'bpmaBH, KOHTO He ca 'IJieffKH Ha EC: Epoe Ha ocl>epnne, aoJIY<1eHH no enexrponeu D'bT:

IlOP'b'IKaTa e B'b3JJO)KeHa Ha rpyna OT BKOHOMJNeCKH orreparopa .UaO HeO V.2.3) ffaHMeHOB8HHe H 8lIDCC Ha H3Il'h.lIHHTeJIJI 1

V.2.4) HH4>opM� OTHOCHO CTOHHOCTTa Ha nop'hqxaTa/o6oco6eHaTa 003� (6ea na ce BKJIJO'IBa MC) Il'spaouaxarma otima apOrH03Ha CTOHHOCT ea D01)1>'1KaTa/06oco6eHaTa D03HUH.R: 2 Ofima CTOHHOCT Ha nopvsxara/ofiocofienara D03HUH.R: HJJH HaH-HHCKa orpepra: I Haa-aacoxa orpepra: KOBTO ca B3eTH npeAB11,U Banyra: (3Q pcu.ocoau cnopQ3yMeHWl - o6UjQ MQKCUMQIIHQ cmoiinocm 3Q mQ3U o6oco6eHQ nosuuus) (3Q OUHOMII'lHU cucmaau 3Q no,cynKU - cmoilnocm HQ nOJJ1>'1KQmQ/ume 3Q mQ3U napmuaa, xosmo/xoumo He e/CQ BKIIJO'leHQ/U B npeOUWHU 06.RB/leH.Wl 3Q 61,3/IQZQHe HQ nOJ)1>'1KU) (sa nop1>t1KU, 6a3upanu HQ pauxoeu cnopasipcenun; QKO mosc ce u3uc1<aa - cmoiiuocm Ha nOJJ1>'1KQmQ/ume 3Q mosu napmuoa, xonmo/xoumo He e/ca BK1110t1eHa/u s npeouumu 06RB11eHWl sc 61,3/IQZQHe HQ n01J1>'1KU)

V.2.5) 11H4>opMaJ.U(JI OTHOCHO B'h3JJ8r8HeTO Ha DO,ll.H3II'hJIHHTeJI/H O JilMa B'b3MO)KffOCT nopusxara .na fu,ne B'b3JIO)KeHa Ha no,n11an'bJIHHTen/11 CTOHHOCT HJIH ,n.RJI OT DOp'b'IKaTa, KOHTO e B'b3M0)Kff0 na 60,naT B'b3JIO)KeHl1 Ha D0,UH3D'bJIHHTeJIH 4 CToHHOCT, fiea na ce BKJIJO'IBa MC: Banyra: .l(.RJI: % Kparxo ODHcaHHe Ha aena OT nopxsxara, KOHTO 1.1..{e fu,ne B'b3JIO)KeH Ha DO,Al130'b.JIHl1Te.11e:

PA3�EJIV: B'b3.7IAI'AHEHAilOP'b'lJKATA 1

Ilopo'!Ka NQ (.l(oroaop NQ): Ofiocofiena D03HUWI NQ: 2 37. 2, 37. 4, 37. 5 HaHMeuoeaHHe: II - pa rpyna ACE MHXMOMTOpM Bo3JIO)KeHa e nopssxa/oeocoeeaa ao3HUHJI

V.1) HH4>opM� OTHOCHO HeB'h3.llaraHe .UaO He�

YHII: c6d020ca·blb9·4a0d-b987-d6b4S8968c2S 33